<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">28858994</PMID>
        <DateRevised>
            <Year>2017</Year>
            <Month>09</Month>
            <Day>29</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1744-6880</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>27</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacogenetics and genomics</Title>
                <ISOAbbreviation>Pharmacogenet. Genomics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants.</ArticleTitle>
            <Pagination>
                <MedlinePgn>416-419</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/FPC.0000000000000308</ELocationID>
            <Abstract>
                <AbstractText>The ATP-binding cassette transporters B1 (ABCB1) and G2 (ABCG2) are both expressed in the intestine and known as efflux transporters of drugs. Dolutegravir was identified recently as a substrate of both ABCB1 and ABCG2. This study aimed to determine the relations between single-nucleotide polymorphisms of ABCB1 and ABCG2 genes and plasma dolutegravir concentrations. Plasma samples were obtained from 42 HIV-1-infected patients treated with dolutegravir-containing regimens 0.5-4 h after dolutegravir dosing. Plasma dolutegravir concentrations were measured by liquid chromatography-mass spectrometry. Genomic DNA was isolated from peripheral blood mononuclear cells. Genotyping of allelic variants of ABCB1 1236 C&gt;T (rs1128503), 2677 G&gt;T/A (rs2032582), 3435 C&gt;T (rs1045642), 4036 A&gt;G (rs3842), and ABCG2 421 C&gt;A (rs2231142) was performed using the TaqMan drug metabolism assays. None of the genotypes in ABCB1 1236 C&gt;T, 2677 G&gt;T/A, 3435 C&gt;T, and 4036 A&gt;G correlated with plasma dolutegravir concentration. In contrast, the mean peak plasma concentration of dolutegravir was significantly higher in the genotypes of ABCG2 421 AA (5002 ng/ml, n=3) compared with the genotypes of ABCG2 421 CC (2569 ng/ml, n=22) and ABCG2 421 CA (2479 ng/ml, n=17) (P=0.0005). The speculated peak level of plasma dolutegravir concentration was significantly higher in ABCG2 genetic variant holders, probably, at least in part, because of low expression levels of efflux transporters in the intestines associated with these genetic variants.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tsuchiya</LastName>
                    <ForeName>Kiyoto</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>aAIDS Clinical Center bDepartment of Pharmacy, National Center for Global Health and Medicine cDepartment of Clinical Pharmacology, Group for Translational Research Support Core, National Cancer Center Research Institute, Tokyo dDepartment of Medical Oncology and Translational Research eCenter for AIDS Research, Kumamoto University, Kumamoto, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hayashida</LastName>
                    <ForeName>Tsunefusa</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hamada</LastName>
                    <ForeName>Akinobu</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oki</LastName>
                    <ForeName>Sakurako</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oka</LastName>
                    <ForeName>Shinichi</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gatanaga</LastName>
                    <ForeName>Hiroyuki</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Pharmacogenet Genomics</MedlineTA>
            <NlmUniqueID>101231005</NlmUniqueID>
            <ISSNLinking>1744-6872</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28858994</ArticleId>
            <ArticleId IdType="doi">10.1097/FPC.0000000000000308</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28049954</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>02</Month>
            <Day>03</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>02</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1347-5215</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>40</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2017</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Biological &amp; pharmaceutical bulletin</Title>
                <ISOAbbreviation>Biol. Pharm. Bull.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>No Effect of SLCO1B1 and CYP3A4/5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Male Subjects.</ArticleTitle>
            <Pagination>
                <MedlinePgn>88-96</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1248/bpb.b16-00686</ELocationID>
            <Abstract>
                <AbstractText>Ticagrelor is a direct-acting P2Y12 receptor antagonist. It is rapidly absorbed and partly metabolized to the active metabolite AR-C124910XX by CYP3A4 and CYP3A5. Three genetic loci (SLCO1B1, CYP3A4, and UGT2B7) were reported to affect ticagrelor pharmacokinetics. This study aimed to investigate the possible effects of SLCO1B1 and CYP3A4/5 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy Chinese male volunteers. Eighteen healthy male volunteers who participated in pharmacogenetics study of ticagrelor were genotyped for SLCO1B1 rs113681054, SLCO1B1*5 (rs4149056), CYP3A4*1G (rs2242480), and CYP3A5*3 (rs776746). All subjects received a single 180 mg loading dose of ticagrelor and then series blood samples were collected from 0 to 48 h. Plasma concentrations of ticagrelor and AR-C124910XX were determined by the high performance liquid chromatography-tandem mass spectrometry method. Inhibition in platelet aggregation (IPA) was assessed and the area under the time-effect curve (AUEC) for the IPA was calculated as pharmacodynamic parameters. No significant difference in ticagrelor pharmacokinetics among genotypes of the two genes was observed. The AUEC did not differ significantly among genotypes of candidate single nucleotide polymorphisms (SNPs). Our data suggest that common genetic variants in SLCO1B1 and CYP3A4/5 may have no effect on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy Chinese volunteers.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Mupeng</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Pharmacology, Xiangya Hospital, Central South University.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Yaodong</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Huilan</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wen</LastName>
                    <ForeName>Zhipeng</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hu</LastName>
                    <ForeName>Xiaolei</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Daoyu</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yanjiao</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xiao</LastName>
                    <ForeName>Jian</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tang</LastName>
                    <ForeName>Jie</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Xiaoping</ForeName>
                    <Initials>X</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>Biol Pharm Bull</MedlineTA>
            <NlmUniqueID>9311984</NlmUniqueID>
            <ISSNLinking>0918-6158</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C561701">AR C124910XX</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D058919">Purinergic P2 Receptor Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C503999">SLCO1B1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D027381">Solute Carrier Organic Anion Transporter Family Member 1b1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.13.67</RegistryNumber>
                <NameOfSubstance UI="C510163">CYP3A4 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="C510164">CYP3A5 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D051544">Cytochrome P-450 CYP3A</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>GLH0314RVC</RegistryNumber>
                <NameOfSubstance UI="C503700">Ticagrelor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>K72T3FS567</RegistryNumber>
                <NameOfSubstance UI="D000241">Adenosine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044466" MajorTopicYN="N">Asian Continental Ancestry Group</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051544" MajorTopicYN="N">Cytochrome P-450 CYP3A</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010974" MajorTopicYN="N">Platelet Aggregation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010975" MajorTopicYN="Y">Platelet Aggregation Inhibitors</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058919" MajorTopicYN="Y">Purinergic P2 Receptor Antagonists</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D027381" MajorTopicYN="N">Solute Carrier Organic Anion Transporter Family Member 1b1</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>1</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>1</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>2</Month>
                <Day>6</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28049954</ArticleId>
            <ArticleId IdType="doi">10.1248/bpb.b16-00686</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">17627617</PMID>
        <DateCompleted>
            <Year>2007</Year>
            <Month>10</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>12</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1347-9032</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>98</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer science</Title>
                <ISOAbbreviation>Cancer Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C&gt;A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1461-7</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The objectives of the present study were (i) to study the pharmacogenetics of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C&gt;A in three distinct healthy Asian populations (Chinese, Malays and Indians), and (ii) to investigate the polygenic influence of these polymorphic variants in irinotecan-induced neutropenia in Asian cancer patients. Pharmacokinetic and pharmacogenetic analyses were done after administration of irinotecan as a 90-min intravenous infusion of 375 mg/m(2) once every 3 weeks (n = 45). Genotypic-phenotypic correlates showed a non-significant influence of UGT1A1*28 and ABCG2 c.421C&gt;A polymorphisms on the pharmacokinetics of SN-38 (P &gt; 0.05), as well as severity of neutropenia (P &gt; 0.05). Significantly higher exposure levels to SN-38 (P = 0.018), lower relative extent of glucuronidation (REG; P = 0.006) and higher biliary index (BI; P = 0.003) were found in cancer patients homozygous for the UGT1A1*6 allele compared with patients harboring the reference genotype. The mean absolute neutrophil count (ANC) was 85% lower and the prevalence of grade 4 neutropenia (ANC &lt; or = 500/microL) was 27% in patients homozygous for UGT1A1*6 compared with the reference group. Furthermore, the presence of the UGT1A1*6 allele was associated with an approximately 3-fold increased risk of developing severe grade 4 neutropenia compared with patients harboring the reference genotype. These exploratory findings suggest that homozygosity for UGT1A1*6 allele may be associated with altered SN-38 disposition and may increase the risk of severe neutropenia in Asian cancer patients, particularly in the Chinese cancer patients who comprised 80% (n = 36) of the patient population in the present study.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jada</LastName>
                    <ForeName>Srinivasa Rao</ForeName>
                    <Initials>SR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Clinical Pharmacology, Division of Medical Sciences, Humphrey Oei Institute of Cancer Research, National Cancer Center, 11 Hospital Drive, Singapore 169610.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lim</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wong</LastName>
                    <ForeName>Chiung Ing</ForeName>
                    <Initials>CI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shu</LastName>
                    <ForeName>Xiaochen</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Soo Chin</ForeName>
                    <Initials>SC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhou</LastName>
                    <ForeName>Qingyu</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goh</LastName>
                    <ForeName>Boon Cher</ForeName>
                    <Initials>BC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chowbay</LastName>
                    <ForeName>Balram</ForeName>
                    <Initials>B</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2007</Year>
                <Month>07</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Cancer Sci</MedlineTA>
            <NlmUniqueID>101168776</NlmUniqueID>
            <ISSNLinking>1347-9032</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C116614">ABCG2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000070997">ATP Binding Cassette Transporter, Sub-Family G, Member 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7673326042</RegistryNumber>
                <NameOfSubstance UI="C051890">irinotecan</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.4.1.-</RegistryNumber>
                <NameOfSubstance UI="C418331">UGT1A1 enzyme</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.4.1.17</RegistryNumber>
                <NameOfSubstance UI="D014453">Glucuronosyltransferase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>XT3Z54Z28A</RegistryNumber>
                <NameOfSubstance UI="D002166">Camptothecin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000070997" MajorTopicYN="N">ATP Binding Cassette Transporter, Sub-Family G, Member 2</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002166" MajorTopicYN="N">Camptothecin</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014453" MajorTopicYN="N">Glucuronosyltransferase</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007194" MajorTopicYN="N">India</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008296" MajorTopicYN="N">Malaysia</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009503" MajorTopicYN="N">Neutropenia</DescriptorName>
                <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012846" MajorTopicYN="N">Singapore</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014565" MajorTopicYN="N">Urogenital Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>7</Month>
                <Day>14</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>10</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>7</Month>
                <Day>14</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17627617</ArticleId>
            <ArticleId IdType="pii">CAS541</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1349-7006.2007.00541.x</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">18055561</PMID>
        <DateCompleted>
            <Year>2008</Year>
            <Month>03</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2016</Year>
            <Month>10</Month>
            <Day>19</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1460-2083</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>17</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Mar</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Human molecular genetics</Title>
                <ISOAbbreviation>Hum. Mol. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The neuronal nicotinic receptor subunit genes (CHRNA6 and CHRNB3) are associated with subjective responses to tobacco.</ArticleTitle>
            <Pagination>
                <MedlinePgn>724-34</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Neuronal nicotinic acetylcholine receptors have been implicated in various measures of nicotine dependence. In this paper, we present findings from an exploratory study of single nucleotide polymorphisms (SNPs) in the CHRNB3 and CHRNA6 genes with tobacco and alcohol phenotypes, including frequency of use and three subjective response factors occurring shortly after initiation of use. Subjects were 1056 ethnically diverse adolescents ascertained from clinical and community settings. The most significant associations were found between two CHRNB3 SNPs (rs4950 and rs13280604) and the three subjective response factors to initial tobacco use. These findings were replicated in a separate community sample of 1524 families participating in the National Longitudinal Study of Adolescent Health. Both CHRNB3 SNPs were found to be associated with similar measures of subjective response to tobacco. These results indicate that early subjective response to nicotine may be a valuable endophenotype for genetic studies aimed at uncovering genes contributing to nicotine use and addiction.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zeiger</LastName>
                    <ForeName>Joanna S</ForeName>
                    <Initials>JS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute for Behavioral Genetics, University of Colorado, Boulder, CO 80309, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haberstick</LastName>
                    <ForeName>Brett C</ForeName>
                    <Initials>BC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schlaepfer</LastName>
                    <ForeName>Isabel</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Collins</LastName>
                    <ForeName>Allan C</ForeName>
                    <Initials>AC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Corley</LastName>
                    <ForeName>Robin P</ForeName>
                    <Initials>RP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Crowley</LastName>
                    <ForeName>Thomas J</ForeName>
                    <Initials>TJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hewitt</LastName>
                    <ForeName>John K</ForeName>
                    <Initials>JK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hopfer</LastName>
                    <ForeName>Christian J</ForeName>
                    <Initials>CJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lessem</LastName>
                    <ForeName>Jeffrey</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McQueen</LastName>
                    <ForeName>Matthew B</ForeName>
                    <Initials>MB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rhee</LastName>
                    <ForeName>Soo Hyun</ForeName>
                    <Initials>SH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ehringer</LastName>
                    <ForeName>Marissa A</ForeName>
                    <Initials>MA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>T32 MH015442</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>MH15442</GrantID>
                    <Acronym>MH</Acronym>
                    <Agency>NIMH NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>EY012562</GrantID>
                    <Acronym>EY</Acronym>
                    <Agency>NEI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DA015522</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 HD060726</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DA13956</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DA011015</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HD010333</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>HD031921</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DA012845</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 DA012845</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>DA03194</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>AA015336</GrantID>
                    <Acronym>AA</Acronym>
                    <Agency>NIAAA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P60 DA011015</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2007</Year>
                <Month>11</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Hum Mol Genet</MedlineTA>
            <NlmUniqueID>9208958</NlmUniqueID>
            <ISSNLinking>0964-6906</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C470410">CHRNA6 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C447159">CHRNB4 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011978">Receptors, Nicotinic</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001741" MajorTopicYN="N">African Americans</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003627" MajorTopicYN="N">Data Interpretation, Statistical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044465" MajorTopicYN="N">European Continental Ancestry Group</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006630" MajorTopicYN="N">Hispanic Americans</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011978" MajorTopicYN="N">Receptors, Nicotinic</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D035781" MajorTopicYN="N">Siblings</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012907" MajorTopicYN="N">Smoking</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014029" MajorTopicYN="N">Tobacco Use Disorder</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>12</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>3</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>12</Month>
                <Day>7</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">18055561</ArticleId>
            <ArticleId IdType="pii">ddm344</ArticleId>
            <ArticleId IdType="doi">10.1093/hmg/ddm344</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25673014</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>03</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1435-232X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>60</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of human genetics</Title>
                <ISOAbbreviation>J. Hum. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>273-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/jhg.2015.12</ELocationID>
            <Abstract>
                <AbstractText>The ABCB1 gene encodes the P-glycoprotein (P-gp) that drives the transmembrane efflux of many drugs. The donor ABCB1 polymorphisms have been related with chronic histological damage and long-term renal function among kidney transplanted patients who received cyclosporine A and tacrolimus (Tac). The aim of our study was to determine whether the donor ABCB1 3435 C/T genotype was related with renal function among Tac-treated renal transplanted patients. Kidney donors (n=65) and recipients (n=90) were genotyped for the ABCB1 rs1045642 (c.3435 C/T) and CYP3A5 rs776746 single-nucleotide polymorphisms. The estimated glomerular filtration rate (eGFR) was calculated with the modification of diet in renal disease formulae at five post-transplant times (2 weeks and 1, 3, 6 and 12 months). The recipient ABCB1 and CYP3A5 genotypes had no significant effect on the eGFR at all the post-transplant times. We found significantly lower eGFR values among patients who received a kidney from ABCB1 3435 T carriers (P&lt;0.01). In conclusion, our study confirmed the potential impact of the donor ABCB1 3435 genotype on the post-transplant renal function among patients treated with Tac. </AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tavira</LastName>
                    <ForeName>Beatriz</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genética Molecular- Fundación Renal I. Alvarez de Toledo, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gómez</LastName>
                    <ForeName>Juan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genética Molecular- Fundación Renal I. Alvarez de Toledo, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Díaz-Corte</LastName>
                    <ForeName>Carmen</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Nefrología, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain [2] Departamento de Medicina, Universidad de Oviedo, Oviedo, Spain [3] Red de Investigación Renal-REDINREN, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Coronel</LastName>
                    <ForeName>Diego</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Nefrología, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lopez-Larrea</LastName>
                    <ForeName>Carlos</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Red de Investigación Renal-REDINREN, Madrid, Spain [2] Inmunología, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Suarez</LastName>
                    <ForeName>Beatriz</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratorio de Biología Celular de la Enfermedad Renal-Instituto de Investigacion Sanitaria F. Jiménez Diaz-Universidad Autónoma Madrid, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Coto</LastName>
                    <ForeName>Eliecer</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Genética Molecular- Fundación Renal I. Alvarez de Toledo, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain [2] Departamento de Medicina, Universidad de Oviedo, Oviedo, Spain [3] Red de Investigación Renal-REDINREN, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>02</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Hum Genet</MedlineTA>
            <NlmUniqueID>9808008</NlmUniqueID>
            <ISSNLinking>1434-5161</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C513055">ABCB1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018435">ATP Binding Cassette Transporter, Sub-Family B</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>WM0HAQ4WNM</RegistryNumber>
                <NameOfSubstance UI="D016559">Tacrolimus</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Surg Res. 2012 Dec;178(2):988-95</RefSource>
                <PMID Version="1">22835948</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transplantation. 2003 Oct 27;76(8):1233-5</RefSource>
                <PMID Version="1">14578760</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transplantation. 2004 Oct 27;78(8):1182-7</RefSource>
                <PMID Version="1">15502717</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2008 Apr;18(4):307-15</RefSource>
                <PMID Version="1">18334915</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2013 Aug;23(8):445-8</RefSource>
                <PMID Version="1">23778326</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Intern Med. 1999 Mar 16;130(6):461-70</RefSource>
                <PMID Version="1">10075613</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transplantation. 2005 Feb 27;79(4):499-502</RefSource>
                <PMID Version="1">15729180</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Soc Nephrol. 2003 Jul;14(7):1889-96</RefSource>
                <PMID Version="1">12819250</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Kidney Int. 2005 Jul;68(1):1-13</RefSource>
                <PMID Version="1">15954891</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Dispos. 2006 May;34(5):836-47</RefSource>
                <PMID Version="1">16501005</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Transplant. 2005 Jun;5(6):1306-11</RefSource>
                <PMID Version="1">15888034</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2014 Mar 12;9(3):e91555</RefSource>
                <PMID Version="1">24621983</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8</RefSource>
                <PMID Version="1">10716719</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 2004 Nov;58(5):548-53</RefSource>
                <PMID Version="1">15521904</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Soc Nephrol. 2012 Nov;23 (11):1891-9</RefSource>
                <PMID Version="1">23064017</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Soc Nephrol. 2009 Nov;20(11):2468-80</RefSource>
                <PMID Version="1">19762492</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Transplant. 2005 Oct;19(5):638-43</RefSource>
                <PMID Version="1">16146556</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nephrol Dial Transplant. 2011 Sep;26(9):3046-50</RefSource>
                <PMID Version="1">21677300</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics. 2014 Feb;15(2):179-88</RefSource>
                <PMID Version="1">24444408</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Chem Lab Med. 2011 May;49(5):825-33</RefSource>
                <PMID Version="1">21480817</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2010 Jul;88(1):95-100</RefSource>
                <PMID Version="1">20505666</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics. 2010 May;11(5):703-14</RefSource>
                <PMID Version="1">20415563</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Soc Nephrol. 2005 May;16(5):1501-11</RefSource>
                <PMID Version="1">15772250</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D018435" MajorTopicYN="N">ATP Binding Cassette Transporter, Sub-Family B</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005919" MajorTopicYN="N">Glomerular Filtration Rate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
                <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016030" MajorTopicYN="N">Kidney Transplantation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016559" MajorTopicYN="N">Tacrolimus</DescriptorName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2015</Year>
                <Month>01</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>01</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>3</Month>
                <Day>2</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25673014</ArticleId>
            <ArticleId IdType="pii">jhg201512</ArticleId>
            <ArticleId IdType="doi">10.1038/jhg.2015.12</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">29318894</PMID>
        <DateRevised>
            <Year>2018</Year>
            <Month>07</Month>
            <Day>01</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1744-8042</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>19</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2018</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacogenomics</Title>
                <ISOAbbreviation>Pharmacogenomics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>175-184</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2217/pgs-2017-0187</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">Multiple genetic variants have been associated with variation in tacrolimus (TAC) trough concentrations. Unfortunately, additional studies do not confirm these associations, leading one to question if a reported association is accurate and reliable. We attempted to validate 44 published variants associated with TAC trough concentrations.</AbstractText>
                <AbstractText Label="MATERIALS &amp; METHODS" NlmCategory="METHODS">Genotypes of the variants in our cohort of 1923 kidney allograft recipients were associated with TAC trough concentrations.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Only variants in CYP3A4 and CYP3A5 were significantly associated with variation in TAC trough concentrations in our validation.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There is no evidence that common variants outside the CYP3A4 and CYP3A5 loci are associated with variation in TAC trough concentrations. In the future rare variants may be important and identified using DNA sequencing.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Oetting</LastName>
                    <ForeName>William S</ForeName>
                    <Initials>WS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental &amp; Clinical Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Baolin</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schladt</LastName>
                    <ForeName>David P</ForeName>
                    <Initials>DP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Minneapolis Medical Research Foundation, Minneapolis, MN 55404, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guan</LastName>
                    <ForeName>Weihua</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Remmel</LastName>
                    <ForeName>Rory P</ForeName>
                    <Initials>RP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dorr</LastName>
                    <ForeName>Casey</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Minneapolis Medical Research Foundation, Minneapolis, MN 55404, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mannon</LastName>
                    <ForeName>Roslyn B</ForeName>
                    <Initials>RB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Nephrology, University of Alabama, Birmingham, AL 35233, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matas</LastName>
                    <ForeName>Arthur J</ForeName>
                    <Initials>AJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Israni</LastName>
                    <ForeName>Ajay K</ForeName>
                    <Initials>AK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Minneapolis Medical Research Foundation, Minneapolis, MN 55404, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Hennepin County Medical Center, Minneapolis, MN 55415, USA.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Epidemiology &amp; Community Health, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jacobson</LastName>
                    <ForeName>Pamala A</ForeName>
                    <Initials>PA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Experimental &amp; Clinical Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2018</Year>
                <Month>01</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Pharmacogenomics</MedlineTA>
            <NlmUniqueID>100897350</NlmUniqueID>
            <ISSNLinking>1462-2416</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Pharm Ther. 2011 Oct;36(5):614-24</RefSource>
                <PMID Version="1">21916909</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Iran J Kidney Dis. 2016 May;10(3):156-63</RefSource>
                <PMID Version="1">27225724</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transpl Int. 2013 Oct;26(10):982-9</RefSource>
                <PMID Version="1">23879408</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics J. 2017 Jan;17(1):105-106</RefSource>
                <PMID Version="1">27958377</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2008 Dec 15;24(24):2938-9</RefSource>
                <PMID Version="1">18974171</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2007 Oct;17(10):873-83</RefSource>
                <PMID Version="1">17885626</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2013 Aug 26;8(8):e73405</RefSource>
                <PMID Version="1">23991193</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 2014 Aug;78(2):364-72</RefSource>
                <PMID Version="1">24528196</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Blood Marrow Transplant. 2016 Feb;22(2):268-276</RefSource>
                <PMID Version="1">26325438</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Clin Pharmacol. 2015 Feb;71(2):191-8</RefSource>
                <PMID Version="1">25487141</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transplant Proc. 2016 Jan-Feb;48(1):81-7</RefSource>
                <PMID Version="1">26915847</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacokinet. 2014 Feb;53(2):123-39</RefSource>
                <PMID Version="1">24249597</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Transplant. 2017 Feb;17(2):318-319</RefSource>
                <PMID Version="1">27640398</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ther Drug Monit. 2016 Apr;38(2):223-9</RefSource>
                <PMID Version="1">26829596</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Pharmacokinet. 2014;29(3):249-53</RefSource>
                <PMID Version="1">24351870</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics. 2015;16(3):239-50</RefSource>
                <PMID Version="1">25712187</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Transplant. 2015 Mar;15(3):800-5</RefSource>
                <PMID Version="1">25588704</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transplantation. 2012 Nov 27;94(10):1025-32</RefSource>
                <PMID Version="1">23095803</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics. 2016 Feb;17(3):249-57</RefSource>
                <PMID Version="1">26784512</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics J. 2018 May 22;18(3):501-505</RefSource>
                <PMID Version="1">29160300</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Clin Pharmacol. 2011 Aug;67(8):803-13</RefSource>
                <PMID Version="1">21359536</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics. 2011 Sep;12(9):1293-303</RefSource>
                <PMID Version="1">21806386</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Transplant. 2017 Apr;17(4):1008-1019</RefSource>
                <PMID Version="1">27597269</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Pharmacol Sin. 2017 Mar;38(3):415-423</RefSource>
                <PMID Version="1">28112181</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ther Drug Monit. 2014 Feb;36(1):71-9</RefSource>
                <PMID Version="1">24061445</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Clin Pharmacol Ther. 2013 Jun;51(6):466-74</RefSource>
                <PMID Version="1">23557867</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genome Med. 2015 Oct 01;7:90</RefSource>
                <PMID Version="1">26423053</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ther Drug Monit. 2009 Apr;31(2):187-97</RefSource>
                <PMID Version="1">19258929</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2016 Oct;26(10):462-72</RefSource>
                <PMID Version="1">27434656</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Transplant. 2016 Feb;16(2):574-82</RefSource>
                <PMID Version="1">26485092</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Clin Pharmacol. 2014 Jun;70(6):685-93</RefSource>
                <PMID Version="1">24658827</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ther Drug Monit. 2015 Oct;37(5):581-8</RefSource>
                <PMID Version="1">25565672</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2012 Sep;92(3):366-75</RefSource>
                <PMID Version="1">22871995</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Mol Sci. 2015 Aug 25;16(9):20168-82</RefSource>
                <PMID Version="1">26307985</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2014 Dec;24(12):597-606</RefSource>
                <PMID Version="1">25322286</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Dispos. 2013 Feb;41(2):480-7</RefSource>
                <PMID Version="1">23175667</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2014 Mar 12;9(3):e91555</RefSource>
                <PMID Version="1">24621983</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transplant Proc. 1998 Jun;30(4):1355-8</RefSource>
                <PMID Version="1">9636551</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transplantation. 2010 Dec 27;90(12):1401-8</RefSource>
                <PMID Version="1">21085059</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics J. 2015 Apr;15(2):144-52</RefSource>
                <PMID Version="1">25287072</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Clin Pharmacol. 2014 Aug;70(8):925-31</RefSource>
                <PMID Version="1">24820765</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics. 2015;16(12):1355-65</RefSource>
                <PMID Version="1">26228923</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Pharm Sci. 2016 Feb 15;83:109-13</RefSource>
                <PMID Version="1">26705892</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2014 Jan 21;9(1):e86206</RefSource>
                <PMID Version="1">24465960</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics. 2015 Dec;16(18):2045-54</RefSource>
                <PMID Version="1">26615671</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics. 2015 Jul;16(8):841-54</RefSource>
                <PMID Version="1">26067485</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transplantation. 2017 Aug;101(8):e273-e279</RefSource>
                <PMID Version="1">28452920</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Pharmacokinet. 2013;28(3):274-7</RefSource>
                <PMID Version="1">23149872</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ther Drug Monit. 2015 Jun;37(3):288-95</RefSource>
                <PMID Version="1">25271728</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Exp Clin Transplant. 2015 Apr;13 Suppl 1:197-200</RefSource>
                <PMID Version="1">25894154</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacokinet. 2013 Sep;52(9):751-62</RefSource>
                <PMID Version="1">23633119</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2015 Jun 03;10(6):e0127995</RefSource>
                <PMID Version="1">26039043</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ther Drug Monit. 2014 Dec;36(6):710-5</RefSource>
                <PMID Version="1">24739669</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transplantation. 2011 Feb 15;91(3):300-8</RefSource>
                <PMID Version="1">21206424</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2002 Jan 1;30(1):163-5</RefSource>
                <PMID Version="1">11752281</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharm. 2015 Mar 2;12(3):758-68</RefSource>
                <PMID Version="1">25590378</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics. 2014 Feb;15(2):179-88</RefSource>
                <PMID Version="1">24444408</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Chim Acta. 2015 May 20;445:79-84</RefSource>
                <PMID Version="1">25817604</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bone Marrow Transplant. 2011 Aug;46(8):1113-7</RefSource>
                <PMID Version="1">21102498</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Expert Opin Drug Metab Toxicol. 2016 May;12(5):555-65</RefSource>
                <PMID Version="1">27010623</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Transplant. 2016 Feb 16;21:105-14</RefSource>
                <PMID Version="1">26879833</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Chim Acta. 2007 Aug;383(1-2):133-9</RefSource>
                <PMID Version="1">17568575</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CYP3A5</Keyword>
            <Keyword MajorTopicYN="N">GWAS</Keyword>
            <Keyword MajorTopicYN="N">kidney</Keyword>
            <Keyword MajorTopicYN="N">tacrolimus</Keyword>
            <Keyword MajorTopicYN="N">transplantation</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pmc-release">
                <Year>2019</Year>
                <Month>02</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2018</Year>
                <Month>1</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2018</Year>
                <Month>1</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2018</Year>
                <Month>1</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29318894</ArticleId>
            <ArticleId IdType="doi">10.2217/pgs-2017-0187</ArticleId>
            <ArticleId IdType="pmc">PMC6021962</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24192531</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>05</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>06</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1744-6880</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>23</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacogenetics and genomics</Title>
                <ISOAbbreviation>Pharmacogenet. Genomics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Exploratory analysis of 1936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>675-83</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/FPC.0000000000000007</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Busulfan is used in preparative regimens before stem cell transplantation. There is significant interpatient variability in busulfan pharmacokinetics (PK) and exposure is related to outcome. Polymorphisms in genes encoding glutathione-S-transferases have been associated with busulfan PK but only explain a limited portion of the observed variability.</AbstractText>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim of this study is to identify additional genetic variants associated with busulfan PK by interrogating 1936 variants in 225 genes involved in drug absorption, distribution, metabolism, and excretion (ADME).</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">In an exploratory cohort (n=65), patients who received busulfan were genotyped with the DMET array. Top SNPs and haplotypes associated with busulfan clearance were validated in an independent validation cohort (n=78).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In the exploratory cohort, seven variants were identified to be associated with busulfan clearance (P&lt;0.001). In the validation cohort, only GSTA5 (rs4715354 and rs7746993) remained significantly associated with busulfan clearance (P=0.025).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This is the first study using an exploratory pharmacogenetic approach to explain the interindividual variability in busulfan PK. The role of glutathione-S-transferases was confirmed, but no additional genetic markers involved in drug ADME appear to be associated with busulfan PK.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ten Brink</LastName>
                    <ForeName>Marloes H</ForeName>
                    <Initials>MH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Departments of aClinical Pharmacy and Toxicology bMedical Statistics and Bioinformatics cHematology, Leiden University Medical Center, Leiden, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Swen</LastName>
                    <ForeName>Jesse J</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Böhringer</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wessels</LastName>
                    <ForeName>Judith A M</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van der Straaten</LastName>
                    <ForeName>Tahar</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marijt</LastName>
                    <ForeName>Erik W A</ForeName>
                    <Initials>EW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>von dem Borne</LastName>
                    <ForeName>Peter A</ForeName>
                    <Initials>PA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zwaveling</LastName>
                    <ForeName>Juliëtte</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guchelaar</LastName>
                    <ForeName>Henk-Jan</ForeName>
                    <Initials>HJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Pharmacogenet Genomics</MedlineTA>
            <NlmUniqueID>101231005</NlmUniqueID>
            <ISSNLinking>1744-6872</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007527">Isoenzymes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.5.1.18</RegistryNumber>
                <NameOfSubstance UI="C484555">GSTA1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.5.1.18</RegistryNumber>
                <NameOfSubstance UI="D005982">Glutathione Transferase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.5.1.18</RegistryNumber>
                <NameOfSubstance UI="C119995">glutathione S-transferase alpha</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>G1LN9045DK</RegistryNumber>
                <NameOfSubstance UI="D002066">Busulfan</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002066" MajorTopicYN="N">Busulfan</DescriptorName>
                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002877" MajorTopicYN="N">Chromosomes, Human</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005982" MajorTopicYN="N">Glutathione Transferase</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018380" MajorTopicYN="Y">Hematopoietic Stem Cell Transplantation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007527" MajorTopicYN="N">Isoenzymes</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019172" MajorTopicYN="N">Transplantation Conditioning</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24192531</ArticleId>
            <ArticleId IdType="doi">10.1097/FPC.0000000000000007</ArticleId>
            <ArticleId IdType="pii">01213011-201312000-00004</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">24956253</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>02</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1744-8042</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>15</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacogenomics</Title>
                <ISOAbbreviation>Pharmacogenomics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics.</ArticleTitle>
            <Pagination>
                <MedlinePgn>997-1006</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2217/pgs.14.48</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">Antiretroviral treatment implies a high cost to the healthcare system. The aim of this study was to evaluate the clinical and economic impact of efavirenz (EFV) dose adjustment by monitoring plasma concentrations and pharmacogenetic analysis of the 516G&gt;T CYP2B6 polymorphism.</AbstractText>
                <AbstractText Label="MATERIALS &amp; METHODS" NlmCategory="METHODS">One hundred and ninety HIV patients treated with EFV were studied. Plasma EFV concentrations were measured by HPLC with ultraviolet detection, and pharmacogenetic analysis was performed by Real Time (RT)-PCR.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred and ninety patients initially treated with a standard dose of EFV (600 mg/day) were studied. In 31 (16.3%) patients, EFV dose was reduced. A total of 87.1% of patients were heterozygous/homozygous carriers (GT/TT). CD4(+) count increased while the minimum steady-state plasma concentration and adverse effects decreased significantly after dose adjustment. Considering only the dose reduction, the adjustments accounted for a saving of 43,539 €/year.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The individualization of EFV dosage guided by genotyping 516G&gt;T CYP2B6 and therapeutic drug monitoring could increase the efficiency of EFV use in antiretroviral treatment.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Martín</LastName>
                    <ForeName>Almudena Sánchez</ForeName>
                    <Initials>AS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Servicio de Farmacia, Hospital Univeristario de Salamanca, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gómez</LastName>
                    <ForeName>Alicia Iglesias</ForeName>
                    <Initials>AI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>García-Berrocal</LastName>
                    <ForeName>Belén</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Figueroa</LastName>
                    <ForeName>Salvador Cabrera</ForeName>
                    <Initials>SC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sánchez</LastName>
                    <ForeName>Miguel Cordero</ForeName>
                    <Initials>MC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Calvo Hernández</LastName>
                    <ForeName>María Victoria</ForeName>
                    <Initials>MV</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gonzalez-Buitrago</LastName>
                    <ForeName>Jose Manuel</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valverde Merino</LastName>
                    <ForeName>María Paz</ForeName>
                    <Initials>MP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tovar</LastName>
                    <ForeName>Carmen Bustos</ForeName>
                    <Initials>CB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martín</LastName>
                    <ForeName>Aurelio Fuertes</ForeName>
                    <Initials>AF</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Isidoro-García</LastName>
                    <ForeName>María</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Pharmacogenomics</MedlineTA>
            <NlmUniqueID>100897350</NlmUniqueID>
            <ISSNLinking>1462-2416</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D048588">Benzoxazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="C585599">CYP2B6 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D065702">Cytochrome P-450 CYP2B6</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>JE6H2O27P8</RegistryNumber>
                <NameOfSubstance UI="C098320">efavirenz</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D048588" MajorTopicYN="N">Benzoxazines</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D065702" MajorTopicYN="N">Cytochrome P-450 CYP2B6</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006678" MajorTopicYN="N">HIV</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010597" MajorTopicYN="N">Pharmacogenetics</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CYP2B6</Keyword>
            <Keyword MajorTopicYN="N">HIV</Keyword>
            <Keyword MajorTopicYN="N">antiretroviral treatment</Keyword>
            <Keyword MajorTopicYN="N">efavirenz</Keyword>
            <Keyword MajorTopicYN="N">efficiency</Keyword>
            <Keyword MajorTopicYN="N">pharmacogenetics</Keyword>
            <Keyword MajorTopicYN="N">pharmacokinetics</Keyword>
            <Keyword MajorTopicYN="N">therapeutic drug monitoring</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24956253</ArticleId>
            <ArticleId IdType="doi">10.2217/pgs.14.48</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">21111021</PMID>
        <DateCompleted>
            <Year>2011</Year>
            <Month>04</Month>
            <Day>11</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2011</Year>
            <Month>01</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-2518</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>29</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Jan</Month>
                        <Day>17</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Vaccine</Title>
                <ISOAbbreviation>Vaccine</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Toll-like receptors and cytokines/cytokine receptors polymorphisms associate with non-response to hepatitis B vaccine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>706-11</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2010.11.023</ELocationID>
            <Abstract>
                <AbstractText>It is well documented that 5-10% hepatitis B adult vaccinees are non- and hypo-responders and probably are not adequately protected against hepatitis B virus (HBV) infection. The sequence variations of genes involved in processes such as pathogen recognition, antigen processing and presentation, and differentiation/maturation of lymphocytes may affect the duration and intensity of protective humoral immune response to the hepatitis B vaccine. In this study, frequencies of 53 known SNPs within 21 candidate genes were analyzed among 46 responders and 24 non-responders. Four SNPs (rs2243248, rs1805015, rs1295686 and rs3804100) in IL-4, IL-4RA, IL-13 and TLR2 genes were found significantly associated with the vaccinees' status of serum anti-HBV response triggered by the vaccine (P&lt;0.05). Two SNPs (rs1295686 and rs1805015) also showed significant association with the vaccine-induced immune response when analyzed together with risk factors such as age and gender, by multivariable logistic regression analysis (P&lt;0.05). Further, haplotype analysis showed that the AG haplotype defined by SNPs rs1143633 (IL-1B; intron) and rs1143627 (IL-1B; intron) was present more frequently in non-responders than in responders (P=0.035). Thus, specific SNPs in genes of cytokines/cytokine receptors and TLR2 were associated with status of the hepatitis B vaccine-induced protective humoral immune response.</AbstractText>
                <CopyrightInformation>Copyright © 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Jie</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Microbiology, Peking University Health Science Center, Beijing 100191, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liang</LastName>
                    <ForeName>Zhenglun</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Fengmin</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fang</LastName>
                    <ForeName>Xin</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Shuang</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zeng</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Fengcai</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Xiangmei</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>Tao</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Jie</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhuang</LastName>
                    <ForeName>Hui</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Vaccine</MedlineTA>
            <NlmUniqueID>8406899</NlmUniqueID>
            <ISSNLinking>0264-410X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006510">Hepatitis B Antibodies</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017325">Hepatitis B Vaccines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018121">Receptors, Cytokine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051193">Toll-Like Receptors</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006510" MajorTopicYN="N">Hepatitis B Antibodies</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017325" MajorTopicYN="N">Hepatitis B Vaccines</DescriptorName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018121" MajorTopicYN="N">Receptors, Cytokine</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051193" MajorTopicYN="N">Toll-Like Receptors</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2010</Year>
                <Month>08</Month>
                <Day>02</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>4</Month>
                <Day>13</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21111021</ArticleId>
            <ArticleId IdType="pii">S0264-410X(10)01632-4</ArticleId>
            <ArticleId IdType="doi">10.1016/j.vaccine.2010.11.023</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">21466653</PMID>
        <DateCompleted>
            <Year>2011</Year>
            <Month>10</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2011</Year>
            <Month>04</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1600-6143</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>11</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</Title>
                <ISOAbbreviation>Am. J. Transplant.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1051-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1600-6143.2011.03491.x</ELocationID>
            <Abstract>
                <AbstractText>IL28B gene polymorphisms are associated with the response to antiviral therapy in hepatitis C patients. We investigated the influence of IL28B polymorphisms on the response to therapy before and after liver transplantation (LT). Genotyping of SNPs rs8099917 and rs12979860 was performed in 128 HCV-infected liver transplant recipients and in their donors; all patients underwent antiviral treatment after LT. The prevalence of genotypes rs12979860CC and rs8099917TT was higher in donors than in recipients (50% vs.19%, p &lt; 0.001 and 67% vs. 38%, p &lt; 0.001, respectively). Response to antiviral therapy was significantly higher for recipient genotype rs12979860CC as compared to rs12979860CT/TT both before (100% vs. 48% p = 0.013) and after LT (59% vs. 25% p = 0.002). The figures were almost identical for SNP rs8099917. Sustained virological response after LT was particularly high in patients with favorable recipient and donor genotypes (p &lt; 0.01 for both SNPs). In a subgroup of 34 patients treated while awaiting LT, a favorable donor IL28B genotype was associated with an improved virological response after LT. Our results support a major role of recipient IL28B genotype in the response to antiviral treatment for hepatitis C recurrence. Interestingly, donor genotype also seems to influence the response pattern, especially in recipients who have a favorable IL28B genotype.</AbstractText>
                <CopyrightInformation>©2011 The Authors Journal compilation©2011 The American Society of Transplantation and the American Society of Transplant Surgeons.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Coto-Llerena</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Liver Unit, CIBERehd, IDIBAPS, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pérez-Del-Pulgar</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Crespo</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carrión</LastName>
                    <ForeName>J A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martínez</LastName>
                    <ForeName>S M</ForeName>
                    <Initials>SM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sánchez-Tapias</LastName>
                    <ForeName>J M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Martorell</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Navasa</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Forns</LastName>
                    <ForeName>X</ForeName>
                    <Initials>X</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2011</Year>
                <Month>04</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Transplant</MedlineTA>
            <NlmUniqueID>100968638</NlmUniqueID>
            <ISSNLinking>1600-6135</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C471044">IL28B protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007378">Interleukins</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016174" MajorTopicYN="N">Hepacivirus</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006526" MajorTopicYN="N">Hepatitis C</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007378" MajorTopicYN="N">Interleukins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017093" MajorTopicYN="N">Liver Failure</DescriptorName>
                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016031" MajorTopicYN="N">Liver Transplantation</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019520" MajorTopicYN="N">Living Donors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009927" MajorTopicYN="N">Tissue and Organ Procurement</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>4</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>4</Month>
                <Day>7</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>10</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21466653</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1600-6143.2011.03491.x</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">25676789</PMID>
        <DateCompleted>
            <Year>2015</Year>
            <Month>06</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>12</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1532-6535</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>97</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical pharmacology and therapeutics</Title>
                <ISOAbbreviation>Clin. Pharmacol. Ther.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response.</ArticleTitle>
            <Pagination>
                <MedlinePgn>518-25</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/cpt.89</ELocationID>
            <Abstract>
                <AbstractText>The first-line treatment of hyperuricemia, which causes gout, is allopurinol. The allopurinol response is highly variable, with many users failing to achieve target serum uric acid (SUA) levels. No genome-wide association study (GWAS) has examined the genetic factors affecting allopurinol effectiveness. Using 2,027 subjects in Kaiser Permanente's Genetic Epidemiology Research on Adult Health and Aging (GERA) Cohort, we conducted a GWAS of allopurinol-related SUA reduction, first in the largest ethnic group, non-Hispanic white (NHW) subjects, and then in a stratified transethnic meta-analysis. ABCG2, encoding the efflux pump BCRP, was associated with SUA reduction in NHW subjects (P = 2 × 10(-8) ), and a missense allele (rs2231142) was associated with a reduced response (P = 3 × 10(-7) ) in the meta-analysis. Isotopic uptake studies in cells demonstrated that BCRP transports allopurinol and genetic variants in ABCG2 affect this transport. Collectively, this first GWAS of allopurinol response demonstrates that ABCG2 is a key determinant of response to the drug. </AbstractText>
                <CopyrightInformation>© 2015 American Society for Clinical Pharmacology and Therapeutics.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wen</LastName>
                    <ForeName>C C</ForeName>
                    <Initials>CC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yee</LastName>
                    <ForeName>S W</ForeName>
                    <Initials>SW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liang</LastName>
                    <ForeName>X</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hoffmann</LastName>
                    <ForeName>T J</ForeName>
                    <Initials>TJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kvale</LastName>
                    <ForeName>M N</ForeName>
                    <Initials>MN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Banda</LastName>
                    <ForeName>Y</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jorgenson</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schaefer</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Risch</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Giacomini</LastName>
                    <ForeName>K M</ForeName>
                    <Initials>KM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>DK103729</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>RC2 AG036607</GrantID>
                    <Acronym>AG</Acronym>
                    <Agency>NIA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32 GM067547</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 DK103729</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>GM61390</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 GM061390</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U19 GM061390</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32 GM007175</GrantID>
                    <Acronym>GM</Acronym>
                    <Agency>NIGMS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D017418">Meta-Analysis</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2015</Year>
                <Month>04</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Pharmacol Ther</MedlineTA>
            <NlmUniqueID>0372741</NlmUniqueID>
            <ISSNLinking>0009-9236</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C116614">ABCG2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000070997">ATP Binding Cassette Transporter, Sub-Family G, Member 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006074">Gout Suppressants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>268B43MJ25</RegistryNumber>
                <NameOfSubstance UI="D014527">Uric Acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>63CZ7GJN5I</RegistryNumber>
                <NameOfSubstance UI="D000493">Allopurinol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>BZ114NVM5P</RegistryNumber>
                <NameOfSubstance UI="D008942">Mitoxantrone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Chemother Pharmacol. 2005 Aug;56(2):161-72</RefSource>
                <PMID Version="1">15838659</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Genet. 2006 Dec;2(12):e190</RefSource>
                <PMID Version="1">17194218</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>G3 (Bethesda). 2011 Nov;1(6):457-70</RefSource>
                <PMID Version="1">22384356</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Nov 1;491(7422):56-65</RefSource>
                <PMID Version="1">23128226</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2007 Jul 15;67(14):6965-72</RefSource>
                <PMID Version="1">17638908</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics J. 2013 Feb;13(1):60-9</RefSource>
                <PMID Version="1">21912425</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46</RefSource>
                <PMID Version="1">23024028</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5223-8</RefSource>
                <PMID Version="1">23493553</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Rheumatol Rep. 2013 Feb;15(2):307</RefSource>
                <PMID Version="1">23315156</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Methods. 2012 Feb;9(2):179-81</RefSource>
                <PMID Version="1">22138821</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Res Ther. 2010;12(2):R63</RefSource>
                <PMID Version="1">20370912</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2010 Aug 20;285(34):26107-13</RefSource>
                <PMID Version="1">20566650</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Rheum Dis. 2015 Apr;74(4):661-7</RefSource>
                <PMID Version="1">24431399</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Aug;44(8):955-9</RefSource>
                <PMID Version="1">22820512</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Ethnopharmacol. 2012 Jun 26;142(1):248-52</RefSource>
                <PMID Version="1">22575704</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2008 Oct 3;283(40):26834-8</RefSource>
                <PMID Version="1">18701466</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2002 May 23;417(6887):447-52</RefSource>
                <PMID Version="1">12024214</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2014 Jan 25;383(9914):282</RefSource>
                <PMID Version="1">24461111</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Genet. 2010 Jul;11(7):499-511</RefSource>
                <PMID Version="1">20517342</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 2008 Jun;325(3):859-68</RefSource>
                <PMID Version="1">18364470</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Renal Physiol. 2012 Aug 15;303(4):F527-39</RefSource>
                <PMID Version="1">22647630</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharmacol. 2005 Sep;68(3):800-7</RefSource>
                <PMID Version="1">15955871</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2004 May 7;279(19):19781-9</RefSource>
                <PMID Version="1">15001581</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4134-9</RefSource>
                <PMID Version="1">15743917</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2013 Feb;45(2):145-54</RefSource>
                <PMID Version="1">23263486</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Dispos. 2005 Dec;33(12):1791-5</RefSource>
                <PMID Version="1">16135657</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 2007 Sep;81(3):559-75</RefSource>
                <PMID Version="1">17701901</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Orphanet J Rare Dis. 2011;6:52</RefSource>
                <PMID Version="1">21801394</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Aug;44(8):904-9</RefSource>
                <PMID Version="1">22797727</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genomics. 2011 Aug;98(2):79-89</RefSource>
                <PMID Version="1">21565264</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharm Pharmacol. 2005 Oct;57(10):1305-11</RefSource>
                <PMID Version="1">16259759</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Genet. 2009 Jun;5(6):e1000529</RefSource>
                <PMID Version="1">19543373</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2007 May 1;67(9):4373-81</RefSource>
                <PMID Version="1">17483351</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genomics. 2011 Dec;98(6):422-30</RefSource>
                <PMID Version="1">21903159</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Res Ther. 2010;12(6):223</RefSource>
                <PMID Version="1">21205285</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000070997" MajorTopicYN="N">ATP Binding Cassette Transporter, Sub-Family G, Member 2</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000493" MajorTopicYN="N">Allopurinol</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002140" MajorTopicYN="N">California</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006074" MajorTopicYN="N">Gout Suppressants</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D033461" MajorTopicYN="N">Hyperuricemia</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008942" MajorTopicYN="N">Mitoxantrone</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009363" MajorTopicYN="N">Neoplasm Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010597" MajorTopicYN="N">Pharmacogenetics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014527" MajorTopicYN="N">Uric Acid</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>10</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2015</Year>
                <Month>02</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>2</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>2</Month>
                <Day>14</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2015</Year>
                <Month>6</Month>
                <Day>26</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25676789</ArticleId>
            <ArticleId IdType="doi">10.1002/cpt.89</ArticleId>
            <ArticleId IdType="pmc">PMC4479153</ArticleId>
            <ArticleId IdType="mid">NIHMS700353</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">23774941</PMID>
        <DateCompleted>
            <Year>2014</Year>
            <Month>05</Month>
            <Day>29</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>09</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-1041</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>69</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of clinical pharmacology</Title>
                <ISOAbbreviation>Eur. J. Clin. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>An acenocoumarol dose algorithm based on a South-Eastern European population.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1901-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00228-013-1551-3</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">To develop and validate an algorithm for the prediction of therapeutic dose of acenocoumarol in Romanian patients.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">The inclusion criteria for entry to the study was age ≥ 18 years and starting acenocoumarol treatment for at least one of the following clinical indications: acute deep vein thrombosis of the lower limbs, persistent or permanent atrial fibrillation, and/or the presence of valvular prostheses requiring prolonged oral anticoagulant therapy. The patients were followed up for 3 months. Patients admitted to the internal medicine, cardiology, and geriatrics wards of the Municipal Clinical Hospital, Cluj-Napoca and &quot;Niculae Stăncioiu&quot; Heart Institute between October 2009 and June 2011 who fulfilled the inclusion criteria were included in the study. Clinical and demographic data that could influence the acenocoumarol stable dose were recorded for each patient. Genetic analysis included the genotyping the CYP2C9*2 and *3, and the VKORC1 -1693 G &gt; A polymorphisms. The patients were randomly divided into two groups: (1) the main group on which the development of the clinical and genetic algorithms for acenocoumarol dose prediction was based; (2) the validation group.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The study included 301 patients, of whom 155 were women (51.5 %) and 146 were men (48.5 %). The median age of the patient cohort was 66 (women, 57; men, 73) years. After randomization the main group comprised 200 patients (66.4 %) and the validation group 101 patients (33.6 %). Age and body mass index explained 18.8 % (R (2)) of the variability in acenocoumarol weekly dose in patients in the main group. When the genetic data were added to the algorithm, the CYP2C9*2 and *3 polymorphisms and the VKORC1 -1693 G &gt; A polymorphism accounted for 4.7 and 19. 6 % of acenocoumarol dose variability, respectively. For the main group, we calculated a mean absolute error of 5 mg/week (0.71 mg/day). In the validation group, clinical parameters explained 22.2 % of the weekly acenocoumarol dose variability. Genetic polymorphisms increased the R(2) coefficient to 32.8 %.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We have developed and validated an accurate algorithm for prediction of the stable therapeutic dose of acenocoumarol in a Romania population.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pop</LastName>
                    <ForeName>Tudor Radu</ForeName>
                    <Initials>TR</Initials>
                    <AffiliationInfo>
                        <Affiliation>5th Department of Surgery, Municipal Hospital of Cluj-Napoca, &quot;Iuliu Haţieganu&quot; University of Medicine and Pharmacy Cluj-Napoca, 11th Tăbăcarilor Street, 400139, Cluj-Napoca, Cluj, Romania.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vesa</LastName>
                    <ForeName>Ştefan  Cristian</ForeName>
                    <Initials>Ş</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Trifa</LastName>
                    <ForeName>Adrian Pavel</ForeName>
                    <Initials>AP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Crişan</LastName>
                    <ForeName>Sorin</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Buzoianu</LastName>
                    <ForeName>Anca Dana</ForeName>
                    <Initials>AD</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D064888">Observational Study</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D023361">Validation Studies</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>06</Month>
                <Day>18</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Eur J Clin Pharmacol</MedlineTA>
            <NlmUniqueID>1256165</NlmUniqueID>
            <ISSNLinking>0031-6970</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.13.-</RegistryNumber>
                <NameOfSubstance UI="C450260">CYP2C9 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.13.-</RegistryNumber>
                <NameOfSubstance UI="D065729">Cytochrome P-450 CYP2C9</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D001189">Aryl Hydrocarbon Hydroxylases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.17.4.4</RegistryNumber>
                <NameOfSubstance UI="C578523">VKORC1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.17.4.4</RegistryNumber>
                <NameOfSubstance UI="D064417">Vitamin K Epoxide Reductases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>I6WP63U32H</RegistryNumber>
                <NameOfSubstance UI="D000074">Acenocoumarol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Thromb Res. 2007;120(1):1-10</RefSource>
                <PMID Version="1">17161452</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Haematol. 2011 May;153(3):379-85</RefSource>
                <PMID Version="1">21418179</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Intern Med. 2003 May 6;138(9):714-9</RefSource>
                <PMID Version="1">12729425</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2012;7(7):e41360</RefSource>
                <PMID Version="1">22911785</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA. 2002 Apr 3;287(13):1690-8</RefSource>
                <PMID Version="1">11926893</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Heart J. 2011 Aug;32(15):1909-17</RefSource>
                <PMID Version="1">21636598</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Trends Biochem Sci. 2004 Jun;29(6):289-92</RefSource>
                <PMID Version="1">15276181</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 1997 Oct;44(4):399-401</RefSource>
                <PMID Version="1">9354316</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenetics. 1994 Feb;4(1):39-42</RefSource>
                <PMID Version="1">8004131</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacokinet. 2008;47(9):565-94</RefSource>
                <PMID Version="1">18698879</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 1977 Oct;4(5):559-65</RefSource>
                <PMID Version="1">911605</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2006 Feb;16(2):101-10</RefSource>
                <PMID Version="1">16424822</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Ther. 1988;36(1):131-49</RefSource>
                <PMID Version="1">3277208</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Scand J Gastroenterol. 1997 Oct;32(10):991-4</RefSource>
                <PMID Version="1">9361171</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Pharm Ther. 1998 Aug;23(4):247-55</RefSource>
                <PMID Version="1">9867310</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2006 Jul;80(1):13-22</RefSource>
                <PMID Version="1">16815313</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2008 Jul;84(1):83-9</RefSource>
                <PMID Version="1">18183038</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 1999 Sep;48(3):409-15</RefSource>
                <PMID Version="1">10510154</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Expert Opin Drug Metab Toxicol. 2008 Aug;4(8):1065-74</RefSource>
                <PMID Version="1">18680441</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Rev. 2009;41(2):89-295</RefSource>
                <PMID Version="1">19514967</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chest. 2012 Feb;141(2 Suppl):e44S-e88S</RefSource>
                <PMID Version="1">22315269</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metabol Drug Interact. 2012;27(4):229-34</RefSource>
                <PMID Version="1">23096528</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenetics. 2004 Jan;14(1):27-33</RefSource>
                <PMID Version="1">15128048</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2010 Jun 18;5(6):e11210</RefSource>
                <PMID Version="1">20585445</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Thromb Haemost. 2004 Jun;91(6):1123-8</RefSource>
                <PMID Version="1">15175798</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2004 May;75(5):376-80</RefSource>
                <PMID Version="1">15116049</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Intern Med. 1997 Jan 15;126(2):133-6</RefSource>
                <PMID Version="1">9005747</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Mol Med. 2012 Dec;16(12 ):2919-24</RefSource>
                <PMID Version="1">22863573</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenetics. 1997 Jun;7(3):203-10</RefSource>
                <PMID Version="1">9241660</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Haematol. 2006 Apr;133(2):183-7</RefSource>
                <PMID Version="1">16611310</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Clin Pharmacol. 2010 Mar;66(3):253-60</RefSource>
                <PMID Version="1">20020283</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 1984 Oct;18(4):475-9</RefSource>
                <PMID Version="1">6487488</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Clin Pharmacol. 2008 Feb;64(2):133-57</RefSource>
                <PMID Version="1">18224312</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000074" MajorTopicYN="N">Acenocoumarol</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001189" MajorTopicYN="N">Aryl Hydrocarbon Hydroxylases</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001281" MajorTopicYN="N">Atrial Fibrillation</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D065729" MajorTopicYN="N">Cytochrome P-450 CYP2C9</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044465" MajorTopicYN="N">European Continental Ancestry Group</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006350" MajorTopicYN="Y">Heart Valve Prosthesis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012383" MajorTopicYN="N">Romania</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D064417" MajorTopicYN="N">Vitamin K Epoxide Reductases</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>02</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>06</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>6</Month>
                <Day>19</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">23774941</ArticleId>
            <ArticleId IdType="doi">10.1007/s00228-013-1551-3</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26831894</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>12</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2016</Year>
            <Month>12</Month>
            <Day>30</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2334</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>16</Volume>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Feb</Month>
                        <Day>02</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC infectious diseases</Title>
                <ISOAbbreviation>BMC Infect. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation.</ArticleTitle>
            <Pagination>
                <MedlinePgn>56</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-016-1381-x</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Efavirenz, widely used as part of antiretroviral drug regimens in the treatment of paediatric human immunodeficiency virus infection, has central nervous system side effects. We describe four children presenting with serious, persistent central nervous system adverse events who were found to have elevated plasma efavirenz concentrations as a result of carrying CYP2B6 single nucleotide polymorphisms, known to play a role in the metabolism of EFV. None of the children had a CYP2B6 wildtype haplotype. We believe this is the first case of cerebellar dysfunction associated with efavirenz use to be described in children.</AbstractText>
                <AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">Four black African children, between the ages of 4 and 8 years presenting between 1 and 20 months post-efavirenz initiation, are described. Cerebellar dysfunction, generalised seizures and absence seizures were the range of presenting abnormalities. Plasma efavirenz levels ranged from 20-60 mg/L, 5-15 times the upper limit of the suggested reference range. All abnormal central nervous system manifestations abated after efavirenz discontinuation.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Efavirenz toxicity should always be considered in human immunodeficiency virus-infected children with unexplained central nervous system abnormalities. Our findings further our understanding of the impact of genetic variants on antiretroviral pharmacokinetics in children across various ethnic groups. Screening for potential EFV-toxicity based on the CYP2B6 c.516 SNP alone, may not be adequate.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pinillos</LastName>
                    <ForeName>Francoise</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Empilweni Services and Research Unit (ESRU), Rahima Moosa Mother and Child Hospital, Department of Paediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dandara</LastName>
                    <ForeName>Collet</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pharmacogenetics and Cancer Research Group, Division of Human Genetics, Department of Pathology &amp; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Swart</LastName>
                    <ForeName>Marelize</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pharmacogenetics and Cancer Research Group, Division of Human Genetics, Department of Pathology &amp; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Strehlau</LastName>
                    <ForeName>Renate</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Empilweni Services and Research Unit (ESRU), Rahima Moosa Mother and Child Hospital, Department of Paediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kuhn</LastName>
                    <ForeName>Louise</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Gertrude H. Sergievsky Center, College of Physicians and Surgeons; and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Patel</LastName>
                    <ForeName>Faeezah</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Empilweni Services and Research Unit (ESRU), Rahima Moosa Mother and Child Hospital, Department of Paediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Coovadia</LastName>
                    <ForeName>Ashraf</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Empilweni Services and Research Unit (ESRU), Rahima Moosa Mother and Child Hospital, Department of Paediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abrams</LastName>
                    <ForeName>Elaine</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>ICAP, Mailman School of Public Health, and College of Physicians &amp; Surgeons Columbia University, 722 W168th street, New York, NY, 10032, USA. eja1@columbia.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 HD061255</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>02</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BMC Infect Dis</MedlineTA>
            <NlmUniqueID>100968551</NlmUniqueID>
            <ISSNLinking>1471-2334</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D048588">Benzoxazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="C585599">CYP2B6 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D065702">Cytochrome P-450 CYP2B6</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>JE6H2O27P8</RegistryNumber>
                <NameOfSubstance UI="C098320">efavirenz</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Pediatr Infect Dis. 2003 Oct;14(4):286-94</RefSource>
                <PMID Version="1">14724793</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 2003 Jul;306(1):287-300</RefSource>
                <PMID Version="1">12676886</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AIDS. 2004 Dec 3;18(18):2391-400</RefSource>
                <PMID Version="1">15622315</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2005 Dec;15(12):861-73</RefSource>
                <PMID Version="1">16272958</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Intern Med. 2005 Nov 15;143(10):714-21</RefSource>
                <PMID Version="1">16287792</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Infect Dis. 2006 Feb 1;42(3):408-10</RefSource>
                <PMID Version="1">16392090</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Infect Dis. 2009 Sep 15;200(6):955-64</RefSource>
                <PMID Version="1">19659438</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>HIV Med. 2009 Sep;10(8):520-3</RefSource>
                <PMID Version="1">19486190</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AIDS. 2009 Oct 23;23(16):2222-3</RefSource>
                <PMID Version="1">19773634</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>HIV Clin Trials. 2009 Nov-Dec;10(6):343-55</RefSource>
                <PMID Version="1">20133265</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AIDS Rev. 2010 Apr-Jun;12(2):67-75</RefSource>
                <PMID Version="1">20571601</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AIDS Behav. 2011 Nov;15(8):1803-18</RefSource>
                <PMID Version="1">21484283</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatr Infect Dis J. 2011 Nov;30(11):1001-3</RefSource>
                <PMID Version="1">21633320</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet Infect Dis. 2012 Jul;12(7):521-30</RefSource>
                <PMID Version="1">22424722</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2012 Dec;22(12):858-67</RefSource>
                <PMID Version="1">23080225</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ther Drug Monit. 2013 Feb;35(1):78-83</RefSource>
                <PMID Version="1">23172109</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2013 Aug;23(8):415-27</RefSource>
                <PMID Version="1">23778320</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AIDS. 2013 Jun 1;27(9):1403-12</RefSource>
                <PMID Version="1">23343913</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Antimicrob Chemother. 2014 Feb;69(2):491-9</RefSource>
                <PMID Version="1">24080498</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Antiviral Res. 2014 Feb;102:44-53</RefSource>
                <PMID Version="1">24316028</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2014;9(1):e86919</RefSource>
                <PMID Version="1">24497997</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J STD AIDS. 2014 Mar;25(3):193-200</RefSource>
                <PMID Version="1">23970651</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2014 Apr 26;383(9927):1474-82</RefSource>
                <PMID Version="1">24522178</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics. 2014 May;15(7):997-1006</RefSource>
                <PMID Version="1">24956253</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Antimicrob Chemother. 2014 Aug;69(8):2175-82</RefSource>
                <PMID Version="1">24729586</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):422-9</RefSource>
                <PMID Version="1">25850607</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Clin Pharmacol. 2006 Apr;62(4):267-75</RefSource>
                <PMID Version="1">16506047</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):280-5</RefSource>
                <PMID Version="1">17356468</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 2007 Sep;64(3):391-5</RefSource>
                <PMID Version="1">17391322</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Infect Dis. 2007 Nov 15;45(10):e128-30</RefSource>
                <PMID Version="1">17968817</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Clin Pharmacol. 2008 Apr;64(4):357-65</RefSource>
                <PMID Version="1">18057928</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 2008 Apr;325(1):284-92</RefSource>
                <PMID Version="1">18171905</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Antimicrob Chemother. 2008 Apr;61(4):914-8</RefSource>
                <PMID Version="1">18281305</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Antimicrob Chemother. 2008 Jun;61(6):1336-9</RefSource>
                <PMID Version="1">18343800</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Antivir Ther. 2008;13(6):779-87</RefSource>
                <PMID Version="1">18839779</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2009 Apr;19(4):300-9</RefSource>
                <PMID Version="1">19238117</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Infect Dis. 2009 Mar 15;199(6):872-80</RefSource>
                <PMID Version="1">19239339</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AIDS. 2001 Jan 26;15(2):241-3</RefSource>
                <PMID Version="1">11216933</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AIDS. 2001 Jan 5;15(1):71-5</RefSource>
                <PMID Version="1">11192870</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Antimicrob Agents Chemother. 2009 Jul;53(7):2791-8</RefSource>
                <PMID Version="1">19433561</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatrics. 2003 Mar;111(3):e275-81</RefSource>
                <PMID Version="1">12612284</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Dispos. 2004 Dec;32(12):1341-4</RefSource>
                <PMID Version="1">15383491</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
                <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D048588" MajorTopicYN="N">Benzoxazines</DescriptorName>
                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
                <QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D065702" MajorTopicYN="N">Cytochrome P-450 CYP2B6</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2015</Year>
                <Month>10</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>01</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>2</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>2</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26831894</ArticleId>
            <ArticleId IdType="doi">10.1186/s12879-016-1381-x</ArticleId>
            <ArticleId IdType="pii">10.1186/s12879-016-1381-x</ArticleId>
            <ArticleId IdType="pmc">PMC4735961</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28063968</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>05</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-0720</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>99</Volume>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Mar</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</Title>
                <ISOAbbreviation>Eur J Pharm Sci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Lack of genetic association between OCT1, ABCB1, and UGT2B7 variants and morphine pharmacokinetics.</ArticleTitle>
            <Pagination>
                <MedlinePgn>337-342</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0928-0987(16)30580-2</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejps.2016.12.039</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">A high inter-individual variation in the pharmacokinetics and pharmacodynamics of morphine has been observed. Genetic polymorphisms in genes encoding the organic cation transporter isoform 1 (OCT1), the efflux transporter p-glycoprotein (ABCB1), and the UDP-glucuronosyltransferase-2B7 (UGT2B7) may influence morphine pharmacokinetics and thus, also pharmacodynamics. The aim of this study was to evaluate the association between OCT1, ABCB1, and UGT2B7 variants, and morphine pharmacokinetics and -dynamics in healthy volunteers.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Pharmacokinetic and pharmacodynamic data were collected from a double-blinded, randomized, crossover trial in 37 healthy subjects. Pharmacokinetic data were analyzed in NONMEM®, and the time-concentration relationship of morphine, morphine-3-glucuronide, and morphine-6-glucuronide was parameterized as the transit compartment rate constant (k<sub>tr</sub>), clearance (CL), and volume of distribution (V<sub>D</sub>). The area under the plasma concentration-time curve (AUC<sub>0-150min</sub>) and the maximum plasma concentration (C<sub>max</sub>) were also calculated. Pharmacodynamic data were measured as pain tolerance thresholds to mechanical stimulation of the rectum and muscle, as well as tonic cold pain stimulation (&quot;the cold pressor test&quot; where hand was immersed in cold water). Six different single nucleotide polymorphisms in three different genes (OCT1 (n=22), ABCB1 (n=37), and UGT2B (n=22)) were examined.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Neither AUC<sub>0-150min</sub>, k<sub>tr</sub>, CL, nor V<sub>D</sub> were associated with genetic variants in OCT1, ABCB1, and UGT2B7 (all P&gt;0.05). Similarly, the antinociceptive effects of morphine on rectal, muscle, and cold pressor tests were not associated with these genetic variants (all P&gt;0.05).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this experimental study in healthy volunteers, we found no association between different genotypes of OCT1, ABCB1, and UGT2B7, and morphine pharmacokinetics and pharmacodynamics. Nonetheless, due to methodological limitations we cannot exclude that associations exist.</AbstractText>
                <CopyrightInformation>Copyright © 2017 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nielsen</LastName>
                    <ForeName>L M</ForeName>
                    <Initials>LM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark; Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sverrisdóttir</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stage</LastName>
                    <ForeName>T B</ForeName>
                    <Initials>TB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Pharmacology, Department of Public Health, University of Southern Denmark, Odense, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feddersen</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brøsen</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Pharmacology, Department of Public Health, University of Southern Denmark, Odense, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Christrup</LastName>
                    <ForeName>L L</ForeName>
                    <Initials>LL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Drewes</LastName>
                    <ForeName>A M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Olesen</LastName>
                    <ForeName>A E</ForeName>
                    <Initials>AE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark; Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Electronic address: aneso@rn.dk.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>04</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Eur J Pharm Sci</MedlineTA>
            <NlmUniqueID>9317982</NlmUniqueID>
            <ISSNLinking>0928-0987</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C513055">ABCB1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018435">ATP Binding Cassette Transporter, Sub-Family B</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050811">Octamer Transcription Factor-1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C494165">POU2F1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>76I7G6D29C</RegistryNumber>
                <NameOfSubstance UI="D009020">Morphine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.4.1.-</RegistryNumber>
                <NameOfSubstance UI="C491474">UGT2B7 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.4.1.17</RegistryNumber>
                <NameOfSubstance UI="D014453">Glucuronosyltransferase</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D018435" MajorTopicYN="N">ATP Binding Cassette Transporter, Sub-Family B</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014453" MajorTopicYN="N">Glucuronosyltransferase</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009020" MajorTopicYN="N">Morphine</DescriptorName>
                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050811" MajorTopicYN="N">Octamer Transcription Factor-1</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Healthy volunteers</Keyword>
            <Keyword MajorTopicYN="N">Interindividual variability</Keyword>
            <Keyword MajorTopicYN="N">Morphine</Keyword>
            <Keyword MajorTopicYN="N">Pharmacogenetics</Keyword>
            <Keyword MajorTopicYN="N">Pharmacokinetics</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>08</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>12</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>1</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>5</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>1</Month>
                <Day>9</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28063968</ArticleId>
            <ArticleId IdType="pii">S0928-0987(16)30580-2</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ejps.2016.12.039</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">19440701</PMID>
        <DateCompleted>
            <Year>2009</Year>
            <Month>08</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>12</Month>
            <Day>09</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-1041</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>65</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of clinical pharmacology</Title>
                <ISOAbbreviation>Eur. J. Clin. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.</ArticleTitle>
            <Pagination>
                <MedlinePgn>667-78</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00228-009-0660-5</ELocationID>
            <Abstract>
                <AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To assess the relationship between genetic polymorphisms and indinavir pharmacokinetic variability and to study the link between concentrations and short-term response or metabolic safety.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Forty protease inhibitor-naive patients initiating highly active antiretroviral therapy (HAART) including indinavir/ritonavir and enrolled in the COPHAR 2-ANRS 111 trial were studied. At week 2, four blood samples were taken before and up to 6 h following drug intake. A population pharmacokinetic analysis was performed using the stochastic approximation expectation maximization (SAEM) algorithm implemented in MONOLIX software. The area under the concentration-time curve (AUC) and maximum (C(max)) and trough concentrations (C(trough)) of indinavir were derived from the population model and tested for their correlation with short-term viral response and safety measurements, while for ritonavir, these same three parameters were tested for their correlation with short-term biochemical safety</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A one-compartment model with first-order absorption and elimination best described both indinavir and ritonavir concentrations. For indinavir, the estimated clearance and volume of distribution were 22.2 L/h and 97.3 L, respectively. The eight patients with the *1B/*1B genotype for the CYP3A4 gene showed a 70% decrease in absorption compared to those with the *1A/*1B or *1A/*1A genotypes (0.5 vs. 2.1, P = 0.04, likelihood ratio test by permutation). The indinavir AUC and C(trough) were positively correlated with the decrease in human immunodeficiency virus RNA between week 0 and week 2 (r = 0.4, P = 0.03 and r = -0.4, P = 0.03, respectively). Patients with the *1B/*1B genotype also had a significantly lower indinavir C(max) (median 3.6, range 2.1-5.2 ng/mL) than those with the *1A/*1B or *1A/*1A genotypes (median 4.4, range 2.2-8.3 ng/mL) (P = 0.04) and a lower increase in triglycerides during the first 4 weeks of treatment (median 0.1, range -0.7 to 1.4 vs. median 0.6, range -0.5 to 1.7 mmol/L, respectively; P = 0.02). For ritonavir, the estimated clearance and volume of distribution were 8.3 L/h and 60.7 L, respectively, and concentrations were not found to be correlated to biochemical safety. Indinavir and ritonavir absorption rate constants were found to be correlated, as well as their apparent volumes of distribution and clearances, indicating correlated bioavailability of the two drugs.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The CYP3A4*1B polymorphism was found to influence the pharmacokinetics of indinavir and, to some extent, the biochemical safety of indinavir.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bertrand</LastName>
                    <ForeName>Julie</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>UMR 738, INSERM, Université Paris Diderot, UFR de Médecine, 16, rue Henri Huchard, 75018, Paris, France. julie.bertrand@inserm.fr</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Treluyer</LastName>
                    <ForeName>Jean-Marc</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Panhard</LastName>
                    <ForeName>Xavière</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tran</LastName>
                    <ForeName>Agnes</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Auleley</LastName>
                    <ForeName>Solange</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rey</LastName>
                    <ForeName>Elisabeth</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Salmon-Céron</LastName>
                    <ForeName>Dominique</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Duval</LastName>
                    <ForeName>Xavier</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mentré</LastName>
                    <ForeName>France</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>COPHAR2-ANRS 111 Study Group</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>05</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Eur J Clin Pharmacol</MedlineTA>
            <NlmUniqueID>1256165</NlmUniqueID>
            <ISSNLinking>0031-6970</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017320">HIV Protease Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5W6YA9PKKH</RegistryNumber>
                <NameOfSubstance UI="D019469">Indinavir</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.13.67</RegistryNumber>
                <NameOfSubstance UI="C510163">CYP3A4 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D051544">Cytochrome P-450 CYP3A</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacokinet. 2007;46(9):739-56</RefSource>
                <PMID Version="1">17713972</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 2007 Sep;64(3):353-62</RefSource>
                <PMID Version="1">17517050</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Antimicrob Chemother. 2008 Jan;61(1):200-5</RefSource>
                <PMID Version="1">17999977</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Neurol. 2008 Jan;65(1):65-70</RefSource>
                <PMID Version="1">18195140</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 2008 Apr;65(4):548-57</RefSource>
                <PMID Version="1">17922881</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biopharm Stat. 2008;18(6):1084-102</RefSource>
                <PMID Version="1">18991109</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2009 Apr;85(4):375-8</RefSource>
                <PMID Version="1">19118379</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fundam Clin Pharmacol. 2009 Aug;23(4):491-500</RefSource>
                <PMID Version="1">19709326</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Infect Dis. 1999 Dec;180(6):1833-7</RefSource>
                <PMID Version="1">10558938</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genetics. 2000 Jun;155(2):945-59</RefSource>
                <PMID Version="1">10835412</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 2001 Jan;51(1):99-102</RefSource>
                <PMID Version="1">11167671</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2001 Mar;69(3):169-74</RefSource>
                <PMID Version="1">11240981</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Acquir Immune Defic Syndr. 2001 Mar 1;26(3):218-24</RefSource>
                <PMID Version="1">11242194</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Acquir Immune Defic Syndr. 2001 Nov 1;28(3):232-9</RefSource>
                <PMID Version="1">11694829</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>HIV Med. 2002 Jan;3(1):37-43</RefSource>
                <PMID Version="1">12059949</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Pharmacother. 2002 Jul-Aug;36(7-8):1230-7</RefSource>
                <PMID Version="1">12086558</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenetics. 2002 Jul;12(5):355-66</RefSource>
                <PMID Version="1">12142725</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94</RefSource>
                <PMID Version="1">12406645</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Metab Dispos. 2002 Dec;30(12):1455-61</RefSource>
                <PMID Version="1">12433819</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Antimicrob Agents Chemother. 2003 Jan;47(1):238-43</RefSource>
                <PMID Version="1">12499197</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2003 Sep;74(3):245-54</RefSource>
                <PMID Version="1">12966368</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biophys Chem. 2003 Sep;105(2-3):221-30</RefSource>
                <PMID Version="1">14499894</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenetics. 2003 Oct;13(10):607-18</RefSource>
                <PMID Version="1">14515059</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Mol Mutagen. 2003;42(4):299-305</RefSource>
                <PMID Version="1">14673875</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Antimicrob Agents Chemother. 2004 Sep;48(9):3226-32</RefSource>
                <PMID Version="1">15328077</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2004 Oct 15;64(20):7426-31</RefSource>
                <PMID Version="1">15492266</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Pharmacol. 1998 Feb;38(2):106-11</RefSource>
                <PMID Version="1">9549640</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 1998 Apr 30;338(18):1281-92</RefSource>
                <PMID Version="1">9562584</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacokinet. 1998 Oct;35(4):275-91</RefSource>
                <PMID Version="1">9812178</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AIDS. 1999 Mar 11;13(4):473-8</RefSource>
                <PMID Version="1">10197375</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharm Sci. 1999 May;88(5):568-73</RefSource>
                <PMID Version="1">10229651</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genetics. 1999 Jul;152(3):821-5</RefSource>
                <PMID Version="1">10388804</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AIDS. 1999 Jul 9;13(10):F63-70</RefSource>
                <PMID Version="1">10416516</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Pharmacother. 1999 Sep;33(9):989-95</RefSource>
                <PMID Version="1">10492504</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ther Drug Monit. 2005 Feb;27(1):63-70</RefSource>
                <PMID Version="1">15665749</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 2005 Feb;59(2):174-82</RefSource>
                <PMID Version="1">15676039</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacokinet. 2005;44(3):279-304</RefSource>
                <PMID Version="1">15762770</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2005 May;77(5):373-87</RefSource>
                <PMID Version="1">15900284</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fundam Clin Pharmacol. 2005 Jun;19(3):373-83</RefSource>
                <PMID Version="1">15910662</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Clin Pharmacol. 2005 Sep;60(3):276-86</RefSource>
                <PMID Version="1">16120066</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>AIDS. 2005 Dec 2;19(18):2127-31</RefSource>
                <PMID Version="1">16284462</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacokinet. 2005;44(12):1267-78</RefSource>
                <PMID Version="1">16372824</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2006 Jun;79(6):570-80</RefSource>
                <PMID Version="1">16765145</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):441-9</RefSource>
                <PMID Version="1">16791115</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2007 Feb;81(2):270-83</RefSource>
                <PMID Version="1">17259951</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacokinet Pharmacodyn. 2007 Apr;34(2):229-49</RefSource>
                <PMID Version="1">17211713</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ther Drug Monit. 2007 Apr;29(2):164-70</RefSource>
                <PMID Version="1">17417069</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D023241" MajorTopicYN="Y">Antiretroviral Therapy, Highly Active</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051544" MajorTopicYN="N">Cytochrome P-450 CYP3A</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017320" MajorTopicYN="N">HIV Protease Inhibitors</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015497" MajorTopicYN="Y">HIV-1</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019469" MajorTopicYN="N">Indinavir</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008657" MajorTopicYN="N">Metabolic Clearance Rate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010597" MajorTopicYN="Y">Pharmacogenetics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">HALMS384935</OtherID>
        <InvestigatorList>
            <Investigator ValidYN="Y">
                <LastName>Salmon-Céron</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Duval</LastName>
                <ForeName>X</ForeName>
                <Initials>X</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mentré</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Auleley</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Biour</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Commoy</LastName>
                <ForeName>M J</ForeName>
                <Initials>MJ</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Diquet</LastName>
                <ForeName>B</ForeName>
                <Initials>B</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Goujard</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Katlama</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lascoux</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Legrand</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Métro</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Peytavin</LastName>
                <ForeName>G</ForeName>
                <Initials>G</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rey</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Taburet</LastName>
                <ForeName>A M</ForeName>
                <Initials>AM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tréluyer</LastName>
                <ForeName>J M</ForeName>
                <Initials>JM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Auleley</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Biour</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Métro</LastName>
                <ForeName>A</ForeName>
                <Initials>A</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lascoux</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Salmon-Céron</LastName>
                <ForeName>D</ForeName>
                <Initials>D</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Duval</LastName>
                <ForeName>X</ForeName>
                <Initials>X</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rey</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tréluyer</LastName>
                <ForeName>J M</ForeName>
                <Initials>JM</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rouzioux</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Piketti</LastName>
                <ForeName>C</ForeName>
                <Initials>C</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Flandre</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zenut</LastName>
                <ForeName>M</ForeName>
                <Initials>M</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Marquet</LastName>
                <ForeName>P</ForeName>
                <Initials>P</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bentata</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mansouri</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Touam</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sereni</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lascoux</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pintado</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Goujard</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mole</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sellier</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bendenoun</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rami</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Parrinello</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Jeantils</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tassi</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Vittecoq</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Teicher</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mallet</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dupont</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lahoulou</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sister Azar</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rosembaum</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Slama</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Naï-Ighil Baakili</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Courtial-Destembert</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Vildé</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Leport</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Duval</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Al Kaied</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Salmon</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Spiridon</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lesprit</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chesnel</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Katlama</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schneider</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Schoen</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Molina</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ponscarme</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Colin de verdière</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Morlat</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bonarek</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Joly</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ralaimazava</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Meridda</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Le Gac</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Raffi</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Allavena</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hüe</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sicot</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Perré</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Leautez</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Aubry</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Suaud</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dellamonica</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rahelinirina</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Michelet</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bouvier</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bazin</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Goubin</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>May</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Boyer</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rouveix</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dupont</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Berthé</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rey</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tréluyer</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Abbara</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Audoul</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tran</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sauvageon</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Poirier</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Taburet</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Vincent</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Aymard</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Peytavin</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lamotte</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dailly</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Garraffo</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lavrut</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mollimard</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Titier</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Tribut</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hulin</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Huet</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Delhotal</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Hoizey</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nicolas-Chanoine</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Sousan</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dény</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Baazia</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Alloui</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Brun-Vézinet</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chams</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fleury</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Pellegrin</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Garrigue</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Fremut</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Vabret</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lebon</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Krivine</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Calvez</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Gourlain</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Amellal</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bouvier-Alias</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Norman</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Idri</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Chambreuil</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Poirier</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mazeron</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Le Faou</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Vénard</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Billaudel</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ferre</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Rouzioux</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Burgard</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Lefevre</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Cottalorda</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Dussaix</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bensidhoum</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Colimon</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Ruffault</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Maillard</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Morinet</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Palmer</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Nicolas</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Zalta</LastName>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Auleley</LastName>
                <ForeName>S</ForeName>
                <Initials>S</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Marcault</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mentré</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Bougen</LastName>
                <ForeName>E</ForeName>
                <Initials>E</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Mentré</LastName>
                <ForeName>F</ForeName>
                <Initials>F</Initials>
            </Investigator>
            <Investigator ValidYN="Y">
                <LastName>Panhard</LastName>
                <ForeName>X</ForeName>
                <Initials>X</Initials>
            </Investigator>
        </InvestigatorList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2009</Year>
                <Month>01</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>04</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19440701</ArticleId>
            <ArticleId IdType="doi">10.1007/s00228-009-0660-5</ArticleId>
            <ArticleId IdType="pmc">PMC2908290</ArticleId>
            <ArticleId IdType="mid">HALMS384935</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">21173786</PMID>
        <DateCompleted>
            <Year>2012</Year>
            <Month>09</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1473-1150</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>12</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The pharmacogenomics journal</Title>
                <ISOAbbreviation>Pharmacogenomics J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes.</ArticleTitle>
            <Pagination>
                <MedlinePgn>255-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/tpj.2010.91</ELocationID>
            <Abstract>
                <AbstractText>The aim of this study is to evaluate whether the quantitative prescription of risperidone (dosage) is related to the patient's metabolic status. Metabolic status was defined in terms of the most relevant polymorphisms of CYP2D6 (*3, *4, *5, *6 and *1xN), CYP3A5 (*3A) and ABCB1 (G2677T) determined a posteriori and blinded to the clinicians. This prospective and observational study includes a cohort of 151 Caucasian psychiatric patients treated with risperidone. Significant differences (Kruskal-Wallis test p=0.01) among the doses administered were observed to correlate (Spearman's r=1, p=0.02) with the different CYP2D6 groups. Poor metabolizers received the lowest doses and ultra rapid metabolizers the highest. No significant correlations were observed with regard to CYP3A5 and ABCB1. We find that, despite not knowing patients' metabolic status, clinicians modify risperidone dosage in order to obtain the best therapeutic option.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mas</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathological Anatomy, Pharmacology and Microbiology, University of Barcelona, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gassò</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alvarez</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parellada</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bernardo</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lafuente</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Pharmacogenomics J</MedlineTA>
            <NlmUniqueID>101083949</NlmUniqueID>
            <ISSNLinking>1470-269X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C513055">ABCB1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018435">ATP Binding Cassette Transporter, Sub-Family B</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D020168">ATP-Binding Cassette, Sub-Family B, Member 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="C510164">CYP3A5 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D019389">Cytochrome P-450 CYP2D6</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.14.1</RegistryNumber>
                <NameOfSubstance UI="D051544">Cytochrome P-450 CYP3A</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>L6UH7ZF8HC</RegistryNumber>
                <NameOfSubstance UI="D018967">Risperidone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D018435" MajorTopicYN="N">ATP Binding Cassette Transporter, Sub-Family B</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020168" MajorTopicYN="N">ATP-Binding Cassette, Sub-Family B, Member 1</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019389" MajorTopicYN="N">Cytochrome P-450 CYP2D6</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051544" MajorTopicYN="N">Cytochrome P-450 CYP3A</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D054796" MajorTopicYN="N">Drug Dosage Calculations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D044465" MajorTopicYN="N">European Continental Ancestry Group</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019545" MajorTopicYN="N">Intuition</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010597" MajorTopicYN="N">Pharmacogenetics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D013030" MajorTopicYN="N">Spain</DescriptorName>
                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>9</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">21173786</ArticleId>
            <ArticleId IdType="pii">tpj201091</ArticleId>
            <ArticleId IdType="doi">10.1038/tpj.2010.91</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Data-Review" Owner="NLM">
        <PMID Version="1">29196725</PMID>
        <DateRevised>
            <Year>2017</Year>
            <Month>12</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2045-2322</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>7</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Dec</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Scientific reports</Title>
                <ISOAbbreviation>Sci Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pharmacogenetic study of seven polymorphisms in three nicotinic acetylcholine receptor subunits in smoking-cessation therapies.</ArticleTitle>
            <Pagination>
                <MedlinePgn>16730</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-017-16946-6</ELocationID>
            <Abstract>
                <AbstractText>Smoking-cessation therapy reduces the risk of smoking-related diseases, but is successful only in a fraction of smokers. There is growing evidence that genetic variations in nicotinic acetylcholine receptor (nAChR) subunits influence the risk of nicotine dependence and the ability to quit smoking. To investigate the role of polymorphisms in nAChR genes on smoking quantity and the outcome of smoking-cessation therapies, we carried out an association study on 337 smokers who underwent pharmacotherapy with varenicline, bupropion, nicotine replacement therapy (NRT) alone, or NRT plus bupropion. Smoking habit and abstention were assessed from the number of cigarettes smoked per day (CPD) and the exhaled CO (eCO), at baseline and up to 12 months. We genotyped seven polymorphisms in genes encoding the nAChR subunits CHRNA4, CHRNA5, and CHRNB2. At baseline, both CPD and eCO were associated with polymorphisms in the CHRNA5 locus (rs503464, rs55853698, rs55781567 and rs16969968; P &lt; 0.01). rs503464, a variant in the 5'-UTR of CHRNA5, was also associated with short-, mid- and long-term responses to therapy (P = 0.011, P = 0.0043, P = 0.020, respectively), although after correction for multiple testing only the association at the mid-term assessment remained significant (FDR = 0.03). These data support the role of individual genetic makeup in the ability to quit smoking.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pintarelli</LastName>
                    <ForeName>Giulia</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Galvan</LastName>
                    <ForeName>Antonella</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Predictive and Preventive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pozzi</LastName>
                    <ForeName>Paolo</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tobacco Control Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Cardiopulmonary Rehabilitation Unit, Azienda Sociosanitaria Territoriale Lariana, Sant'Antonio Abate Hospital, Cantù (CO), Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Noci</LastName>
                    <ForeName>Sara</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pasetti</LastName>
                    <ForeName>Giovanna</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Predictive and Preventive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sala</LastName>
                    <ForeName>Francesca</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Predictive and Preventive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pastorino</LastName>
                    <ForeName>Ugo</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boffi</LastName>
                    <ForeName>Roberto</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Tobacco Control Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Colombo</LastName>
                    <ForeName>Francesca</ForeName>
                    <Initials>F</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-2015-4317</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. francesca.colombo@istitutotumori.mi.it.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Sci Rep</MedlineTA>
            <NlmUniqueID>101563288</NlmUniqueID>
            <ISSNLinking>2045-2322</ISSNLinking>
        </MedlineJournalInfo>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 May;42(5):441-7</RefSource>
                <PMID Version="1">20418890</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Natl Cancer Inst. 2010 Sep 8;102(17):1366-70</RefSource>
                <PMID Version="1">20733116</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuropharmacology. 2007 Mar;52(3):985-94</RefSource>
                <PMID Version="1">17157884</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>JAMA Psychiatry. 2014 Jul 1;71(7):797-805</RefSource>
                <PMID Version="1">24850280</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>MMWR Morb Mortal Wkly Rep. 2011 Nov 11;60(44):1513-9</RefSource>
                <PMID Version="1">22071589</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cochrane Database Syst Rev. 2016 May 09;(5):CD006103</RefSource>
                <PMID Version="1">27158893</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuropharmacology. 2014 Jan;76 Pt B:592-9</RefSource>
                <PMID Version="1">24055496</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Psychiatry. 2015 Mar 1;77(5):493-503</RefSource>
                <PMID Version="1">25555482</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Braz J Med Biol Res. 2013 Jan;46(1):79-84</RefSource>
                <PMID Version="1">23314339</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Tumori. 2015 May-Jun;101(3):306-11</RefSource>
                <PMID Version="1">25838249</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2011;6(8):e23373</RefSource>
                <PMID Version="1">21858091</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes (Basel). 2016 Nov 07;7(11):</RefSource>
                <PMID Version="1">27827986</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Carcinogenesis. 2010 Mar;31(3):331-3</RefSource>
                <PMID Version="1">19910382</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenet Genomics. 2013 Feb;23(2):94-103</RefSource>
                <PMID Version="1">23249876</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 May;42(5):448-53</RefSource>
                <PMID Version="1">20418888</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 2008 Jan 1;75(1):178-95</RefSource>
                <PMID Version="1">17888884</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Trends Pharmacol Sci. 2010 Jan;31(1):46-51</RefSource>
                <PMID Version="1">19896728</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2010 Jun 17;362(24):2295-303</RefSource>
                <PMID Version="1">20554984</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cochrane Database Syst Rev. 2013 May 31;(5):CD009329</RefSource>
                <PMID Version="1">23728690</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 1999 Jan;288(1):88-92</RefSource>
                <PMID Version="1">9862757</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nicotine Tob Res. 2012 Aug;14 (8):993-7</RefSource>
                <PMID Version="1">22180580</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Transl Psychiatry. 2015 Oct 06;5:e651</RefSource>
                <PMID Version="1">26440539</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuropsychopharmacology. 2012 Feb;37(3):641-50</RefSource>
                <PMID Version="1">22048466</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Pharmacol Sin. 2009 Jun;30(6):653-5</RefSource>
                <PMID Version="1">19498413</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chest. 2000 Mar;117(3):758-63</RefSource>
                <PMID Version="1">10713003</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2009 Sep 1;15(17):5599; author reply 5599</RefSource>
                <PMID Version="1">19706810</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacogenomics J. 2014 Feb;14(1):70-6</RefSource>
                <PMID Version="1">23358500</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Pharmacol Ther. 2009 Sep;86(3):263-71</RefSource>
                <PMID Version="1">19536067</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Am Thorac Soc. 2014 Sep;11(7):1003-10</RefSource>
                <PMID Version="1">25072098</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2010 May;42(5):436-40</RefSource>
                <PMID Version="1">20418889</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Hum Genet. 2011 Jan;19(1):76-83</RefSource>
                <PMID Version="1">20700147</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drugs. 2008;68(11):1511-27</RefSource>
                <PMID Version="1">18627208</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Psychiatry. 2009 May;14(5):501-10</RefSource>
                <PMID Version="1">18414406</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2013 Jan 24;368(4):341-50</RefSource>
                <PMID Version="1">23343063</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Psychiatry. 2008 Sep;165(9):1163-71</RefSource>
                <PMID Version="1">18519524</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuropsychopharmacology. 2010 Nov;35(12):2392-402</RefSource>
                <PMID Version="1">20736995</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Med Genet B Neuropsychiatr Genet. 2010 Jan 5;153B(1):17-28</RefSource>
                <PMID Version="1">19475569</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2013 Jan 12;381(9861):133-41</RefSource>
                <PMID Version="1">23107252</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>12</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29196725</ArticleId>
            <ArticleId IdType="doi">10.1038/s41598-017-16946-6</ArticleId>
            <ArticleId IdType="pii">10.1038/s41598-017-16946-6</ArticleId>
            <ArticleId IdType="pmc">PMC5711795</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">28068779</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>06</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>01</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1535-7228</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>174</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>05</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The American journal of psychiatry</Title>
                <ISOAbbreviation>Am J Psychiatry</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Norepinephrine Transporter Gene Variants and Remission From Depression With Venlafaxine Treatment in Older Adults.</ArticleTitle>
            <Pagination>
                <MedlinePgn>468-475</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2016.16050617</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE">The primary objective of this study was to investigate five putatively functional variants of the norepinephrine transporter (SLC6A2, NET) and serotonin transporter (SLC6A4, SERT) genes and remission in depressed older adults treated with venlafaxine. A secondary objective was to analyze 17 other variants in serotonergic system genes (HTR1A, HTR2A, HTR1B, HTR2C, TPH1, TPH2) potentially involved in the mechanism of action of venlafaxine.</AbstractText>
                <AbstractText Label="METHOD">The sample included 350 adults age 60 or older with DSM-IV-defined major depressive disorder and a score of at least 15 on the Montgomery-Åsberg Depression Rating Scale (MADRS). Participants received protocolized treatment with open-label venlafaxine, up to 300 mg/day for approximately 12 weeks, as part of a three-site clinical trial. Each individual was genotyped for 22 polymorphisms in eight genes, which were tested for association with venlafaxine remission (a MADRS score ≤10) and changes in MADRS score during treatment.</AbstractText>
                <AbstractText Label="RESULTS">After adjusting for multiple comparisons, NET variant rs2242446 (T-182C) was significantly associated with remission (odds ratio=1.66, 95% CI=1.13, 2.42). Individuals with the rs2242446 C/C genotype were more likely to remit (73.1%) than those with either the C/T (51.8%) or the T/T genotype (47.3%). Individuals with the C/C genotype also had a shorter time to remission than those with the C/T or T/T genotypes and had a greater percentage change in MADRS score from baseline to end of treatment (up to week 12).</AbstractText>
                <AbstractText Label="CONCLUSIONS">NET rs2242446/T-182C may serve as a biomarker to predict the likelihood of remission with venlafaxine in older adults with major depression. These findings may help to optimize antidepressant outcomes in older adults.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Marshe</LastName>
                    <ForeName>Victoria S</ForeName>
                    <Initials>VS</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Institute of Medical Science, University of Toronto, Toronto; the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Department of Psychiatry, McGill University, Montreal; the Department of Psychiatry and the Department of Pharmacology, University of Toronto, Toronto; the Department of Psychiatry, University of Pittsburgh, Pittsburgh; the Geriatric Research Education and Clinical Center, VA Pittsburgh Health System, Pittsburgh; and the Healthy Mind Lab, Department of Psychiatry, Washington University, St. Louis.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maciukiewicz</LastName>
                    <ForeName>Malgorzata</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Institute of Medical Science, University of Toronto, Toronto; the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Department of Psychiatry, McGill University, Montreal; the Department of Psychiatry and the Department of Pharmacology, University of Toronto, Toronto; the Department of Psychiatry, University of Pittsburgh, Pittsburgh; the Geriatric Research Education and Clinical Center, VA Pittsburgh Health System, Pittsburgh; and the Healthy Mind Lab, Department of Psychiatry, Washington University, St. Louis.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rej</LastName>
                    <ForeName>Soham</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Institute of Medical Science, University of Toronto, Toronto; the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Department of Psychiatry, McGill University, Montreal; the Department of Psychiatry and the Department of Pharmacology, University of Toronto, Toronto; the Department of Psychiatry, University of Pittsburgh, Pittsburgh; the Geriatric Research Education and Clinical Center, VA Pittsburgh Health System, Pittsburgh; and the Healthy Mind Lab, Department of Psychiatry, Washington University, St. Louis.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tiwari</LastName>
                    <ForeName>Arun K</ForeName>
                    <Initials>AK</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Institute of Medical Science, University of Toronto, Toronto; the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Department of Psychiatry, McGill University, Montreal; the Department of Psychiatry and the Department of Pharmacology, University of Toronto, Toronto; the Department of Psychiatry, University of Pittsburgh, Pittsburgh; the Geriatric Research Education and Clinical Center, VA Pittsburgh Health System, Pittsburgh; and the Healthy Mind Lab, Department of Psychiatry, Washington University, St. Louis.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sibille</LastName>
                    <ForeName>Etienne</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Institute of Medical Science, University of Toronto, Toronto; the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Department of Psychiatry, McGill University, Montreal; the Department of Psychiatry and the Department of Pharmacology, University of Toronto, Toronto; the Department of Psychiatry, University of Pittsburgh, Pittsburgh; the Geriatric Research Education and Clinical Center, VA Pittsburgh Health System, Pittsburgh; and the Healthy Mind Lab, Department of Psychiatry, Washington University, St. Louis.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blumberger</LastName>
                    <ForeName>Daniel M</ForeName>
                    <Initials>DM</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Institute of Medical Science, University of Toronto, Toronto; the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Department of Psychiatry, McGill University, Montreal; the Department of Psychiatry and the Department of Pharmacology, University of Toronto, Toronto; the Department of Psychiatry, University of Pittsburgh, Pittsburgh; the Geriatric Research Education and Clinical Center, VA Pittsburgh Health System, Pittsburgh; and the Healthy Mind Lab, Department of Psychiatry, Washington University, St. Louis.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karp</LastName>
                    <ForeName>Jordan F</ForeName>
                    <Initials>JF</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Institute of Medical Science, University of Toronto, Toronto; the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Department of Psychiatry, McGill University, Montreal; the Department of Psychiatry and the Department of Pharmacology, University of Toronto, Toronto; the Department of Psychiatry, University of Pittsburgh, Pittsburgh; the Geriatric Research Education and Clinical Center, VA Pittsburgh Health System, Pittsburgh; and the Healthy Mind Lab, Department of Psychiatry, Washington University, St. Louis.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lenze</LastName>
                    <ForeName>Eric J</ForeName>
                    <Initials>EJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Institute of Medical Science, University of Toronto, Toronto; the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Department of Psychiatry, McGill University, Montreal; the Department of Psychiatry and the Department of Pharmacology, University of Toronto, Toronto; the Department of Psychiatry, University of Pittsburgh, Pittsburgh; the Geriatric Research Education and Clinical Center, VA Pittsburgh Health System, Pittsburgh; and the Healthy Mind Lab, Department of Psychiatry, Washington University, St. Louis.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reynolds</LastName>
                    <ForeName>Charles F</ForeName>
                    <Initials>CF</Initials>
                    <Suffix>3rd</Suffix>
                    <AffiliationInfo>
                        <Affiliation>From the Institute of Medical Science, University of Toronto, Toronto; the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Department of Psychiatry, McGill University, Montreal; the Department of Psychiatry and the Department of Pharmacology, University of Toronto, Toronto; the Department of Psychiatry, University of Pittsburgh, Pittsburgh; the Geriatric Research Education and Clinical Center, VA Pittsburgh Health System, Pittsburgh; and the Healthy Mind Lab, Department of Psychiatry, Washington University, St. Louis.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kennedy</LastName>
                    <ForeName>James L</ForeName>
                    <Initials>JL</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Institute of Medical Science, University of Toronto, Toronto; the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Department of Psychiatry, McGill University, Montreal; the Department of Psychiatry and the Department of Pharmacology, University of Toronto, Toronto; the Department of Psychiatry, University of Pittsburgh, Pittsburgh; the Geriatric Research Education and Clinical Center, VA Pittsburgh Health System, Pittsburgh; and the Healthy Mind Lab, Department of Psychiatry, Washington University, St. Louis.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mulsant</LastName>
                    <ForeName>Benoit H</ForeName>
                    <Initials>BH</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Institute of Medical Science, University of Toronto, Toronto; the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Department of Psychiatry, McGill University, Montreal; the Department of Psychiatry and the Department of Pharmacology, University of Toronto, Toronto; the Department of Psychiatry, University of Pittsburgh, Pittsburgh; the Geriatric Research Education and Clinical Center, VA Pittsburgh Health System, Pittsburgh; and the Healthy Mind Lab, Department of Psychiatry, Washington University, St. Louis.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Müller</LastName>
                    <ForeName>Daniel J</ForeName>
                    <Initials>DJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>From the Institute of Medical Science, University of Toronto, Toronto; the Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto; the Department of Psychiatry, McGill University, Montreal; the Department of Psychiatry and the Department of Pharmacology, University of Toronto, Toronto; the Department of Psychiatry, University of Pittsburgh, Pittsburgh; the Geriatric Research Education and Clinical Center, VA Pittsburgh Health System, Pittsburgh; and the Healthy Mind Lab, Department of Psychiatry, Washington University, St. Louis.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>ClinicalTrials.gov</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>NCT00892047</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016448">Multicenter Study</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>01</Month>
                <Day>10</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Psychiatry</MedlineTA>
            <NlmUniqueID>0370512</NlmUniqueID>
            <ISSNLinking>0002-953X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050484">Norepinephrine Plasma Membrane Transport Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C493227">SLC6A2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7D7RX5A8MO</RegistryNumber>
                <NameOfSubstance UI="D000069470">Venlafaxine Hydrochloride</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Am J Psychiatry. 2017 May 1;174(5):417-418</RefSource>
                <PMID Version="1">28457163</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016013" MajorTopicYN="N">Likelihood Functions</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050484" MajorTopicYN="N">Norepinephrine Plasma Membrane Transport Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName>
                <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D040641" MajorTopicYN="N">Quantitative Trait Loci</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000069470" MajorTopicYN="N">Venlafaxine Hydrochloride</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Antidepressants</Keyword>
            <Keyword MajorTopicYN="Y">Genetics</Keyword>
            <Keyword MajorTopicYN="Y">Late Life</Keyword>
            <Keyword MajorTopicYN="Y">Major Depression</Keyword>
            <Keyword MajorTopicYN="Y">Pharmacogenomics</Keyword>
            <Keyword MajorTopicYN="Y">Venlafaxine</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>1</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>6</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>1</Month>
                <Day>11</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">28068779</ArticleId>
            <ArticleId IdType="doi">10.1176/appi.ajp.2016.16050617</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27095468</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>01</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1024-2708</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>22</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Hong Kong medical journal = Xianggang yi xue za zhi</Title>
                <ISOAbbreviation>Hong Kong Med J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>NUDT15 variant and thiopurine-induced leukopenia in Hong Kong.</ArticleTitle>
            <Pagination>
                <MedlinePgn>185-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.12809/hkmj154783</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wong</LastName>
                    <ForeName>Felix C K</ForeName>
                    <Initials>FC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemical Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leung</LastName>
                    <ForeName>Alex W K</ForeName>
                    <Initials>AW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kwok</LastName>
                    <ForeName>Jeffrey S S</ForeName>
                    <Initials>JS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemical Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chan</LastName>
                    <ForeName>Michael H M</ForeName>
                    <Initials>MH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemical Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>C K</ForeName>
                    <Initials>CK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yuen</LastName>
                    <ForeName>Y P</ForeName>
                    <Initials>YP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemical Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Hong Kong Med J</MedlineTA>
            <NlmUniqueID>9512509</NlmUniqueID>
            <ISSNLinking>1024-2708</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>E7WED276I5</RegistryNumber>
                <NameOfSubstance UI="D015122">Mercaptopurine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.6.1.-</RegistryNumber>
                <NameOfSubstance UI="C543721">MTH2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.1.-</RegistryNumber>
                <NameOfSubstance UI="D011755">Pyrophosphatases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>MRK240IY2L</RegistryNumber>
                <NameOfSubstance UI="D001379">Azathioprine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D001379" MajorTopicYN="N">Azathioprine</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006723" MajorTopicYN="N">Hong Kong</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D007970" MajorTopicYN="N">Leukopenia</DescriptorName>
                <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015122" MajorTopicYN="N">Mercaptopurine</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011755" MajorTopicYN="N">Pyrophosphatases</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>4</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>4</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>1</Month>
                <Day>18</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27095468</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">29061081</PMID>
        <DateRevised>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1744-8042</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>18</Volume>
                    <Issue>16</Issue>
                    <PubDate>
                        <Year>2017</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacogenomics</Title>
                <ISOAbbreviation>Pharmacogenomics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1491-1502</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2217/pgs-2017-0116</ELocationID>
            <Abstract>
                <AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim was to evaluate the effect of polymorphisms in metabolizing enzymes and transporters on the pharmacokinetics, pharmacodynamics and adverse effects of trazodone in healthy volunteers.</AbstractText>
                <AbstractText Label="MATERIALS &amp; METHODS" NlmCategory="METHODS">36 healthy volunteers receiving a single 100-mg oral dose of trazodone were genotyped for 11 variants in CYP3A4, CYP3A5, CYP2D6 and ABCB1 by real-time PCR. Plasma concentrations were measured using liquid chromatography-tandem mass spectrometry method.</AbstractText>
                <AbstractText Label="RESULTS &amp; CONCLUSION" NlmCategory="CONCLUSIONS">Sex affected the pharmacokinetics of trazodone with higher clearance in women. Polymorphisms in ABCB1, but not in CYP3A or CYP2D6, influenced trazodone pharmacokinetics. Trazodone decreased blood pressure and prolonged the corrected QT interval interval. CYP2D6 and ABCB1 polymorphisms were associated with the incidence of dizziness and prolonged corrected QT interval, respectively. Subjects with adverse drug reactions had lower concentrations of trazodone suggesting its metabolite (m-chlorophenylpiperazine) could be responsible for these effects.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Saiz-Rodríguez</LastName>
                    <ForeName>Miriam</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Belmonte</LastName>
                    <ForeName>Carmen</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Derqui-Fernández</LastName>
                    <ForeName>Nieves</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cabaleiro</LastName>
                    <ForeName>Teresa</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Román</LastName>
                    <ForeName>Manuel</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>UICEC Hospital Universitario de la Princesa, Plataforma SCReN (Spanish Clinical Reseach Network), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ochoa</LastName>
                    <ForeName>Dolores</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>UICEC Hospital Universitario de la Princesa, Plataforma SCReN (Spanish Clinical Reseach Network), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Talegón</LastName>
                    <ForeName>María</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ovejero-Benito</LastName>
                    <ForeName>María C</ForeName>
                    <Initials>MC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abad-Santos</LastName>
                    <ForeName>Francisco</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Pharmacology Department, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>UICEC Hospital Universitario de la Princesa, Plataforma SCReN (Spanish Clinical Reseach Network), Instituto de Investigación Sanitaria la Princesa (IP), Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Pharmacogenomics</MedlineTA>
            <NlmUniqueID>100897350</NlmUniqueID>
            <ISSNLinking>1462-2416</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">ABCB1</Keyword>
            <Keyword MajorTopicYN="N">CYP2D6</Keyword>
            <Keyword MajorTopicYN="N">CYP3A</Keyword>
            <Keyword MajorTopicYN="N">pharmacodynamics</Keyword>
            <Keyword MajorTopicYN="N">pharmacokinetics</Keyword>
            <Keyword MajorTopicYN="N">polymorphisms</Keyword>
            <Keyword MajorTopicYN="N">safety</Keyword>
            <Keyword MajorTopicYN="N">trazodone</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2017</Year>
                <Month>10</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">29061081</ArticleId>
            <ArticleId IdType="doi">10.2217/pgs-2017-0116</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>